

1 [Key reference using this protocol](#) :

2 “Zhao, S. et al. Cell. 180, 796-812 (2020) [10.1016/j.cell.2020.01.030]”.

# 3 **Scalable SHANEL Tissue Labelling and** 4 **Clearing for Intact Human Organs**

5  
6 Hongcheng Mai<sup>1,2,3,\*</sup>, Zhouyi Rong<sup>1,2,3,\*</sup>, Shan Zhao<sup>1,2,3,\*</sup>, Ruiyao Cai<sup>1,2</sup>,  
7 Hanno Steinke<sup>4</sup>, Ingo Bechmann<sup>4</sup> and Ali Ertürk<sup>1,2,5</sup>

8  
9 <sup>1</sup> Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Center, Neuherberg,  
10 Munich, Germany

11 <sup>2</sup> Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians University  
12 Munich, Munich, Germany

13 <sup>3</sup> Munich Medical Research School (MMRS), Ludwig-Maximilians University Munich, Munich, Germany

14 <sup>4</sup> Institute of Anatomy, University of Leipzig, Leipzig, Germany

15 <sup>5</sup> Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

16  
17 \*These authors contributed equally

18 Correspondence: [erturk@helmholtz-muenchen.de](mailto:erturk@helmholtz-muenchen.de)

## 19 20 **Abstract**

21 Advances in tissue labelling and clearing methods include improvement of tissue  
22 transparency, better preservation of fluorescent signal, compatibility of immunostaining and  
23 feasibility for large sample volume. However, existing methods share the common limitation  
24 that they can only be applied to human tissue slices, thus rendering intact human organs  
25 transparent remains a challenge. In this work, we describe experimental details of the Small-  
26 micelle-mediated Human orgAN Efficient clearing and Labelling (SHANEL) pipeline, that can  
27 be applied for cellular mapping of intact human organs. We have successfully cleared  
28 multiple human organs including kidney, pancreas, heart, lung, spleen and brain, as well as  
29 hard tissue like skull. This protocol illustrates the complete process of labelling and clearing  
30 whole human organs as well as handling corresponding large image datasets within weeks  
31 to months based on the organ types and sizes.

## 32 33 **Introduction**

34 Three-dimensional (3D) mapping of the human organs at cellular resolution and generating  
35 reference maps of organs across ages or diseases represent the common perspectives of  
36 diverse consortiums including HuBMAP (Human Biomolecular Atlas Program)<sup>1,2</sup>, Human Cell  
37 Atlas<sup>3</sup>, Human Tumour Atlas<sup>4</sup>, and LungMap<sup>5</sup>. Traditional histological techniques of slicing,  
38 staining, imaging and 3D reconstruction of cellular details of biological tissue pieces would  
39 receive feasibility and scalability challenges when dealing with big-sized human organs. For  
40 example, mapping one intact adult human brain took years of tedious work, not mentioning  
41 the mechanical distortion and accidental loss of sections during the lengthy process<sup>6</sup>. While  
42 improvements are being constantly developed in the apparatus and iterative image analysis

43 of multimodality imaging of human organs using PET/MRI, these modalities are still limited  
44 by low resolution and the lack of an ability to probe cellular and molecular parameters.

45  
46 Recently, extensive biomedical research including in neuroscience<sup>7-12</sup>, development<sup>13</sup>, and  
47 cancer<sup>14,15</sup> significantly benefited from the optical tissue labelling and clearing methods that  
48 bypass major problems of histology. Especially, clearing and imaging of whole adult mouse  
49 bodies opened a holistic examination window into physiological and pathological systems in  
50 an unbiased way<sup>9,14</sup>. However, human organs obviously are much larger in size, and contain  
51 more complex tissue components due to aging, which are limiting the post-staining methods  
52 comparing to months-year old rodent organs. Therefore, whole human organ transparency  
53 has been challenging, despite numerous trials on slices<sup>11,16-19</sup>. Hence, we developed a full  
54 pipeline of whole human organ labelling, clearing, imaging and 3D map reconstruction at  
55 cellular level, which implemented a new tissue labelling and clearing technology termed  
56 SHANEL and an advanced volumetric imaging system from commercialized light-sheet  
57 fluorescence microscope (LSFM)<sup>20</sup>. This pipeline is easy-to-be-adopted in laboratories, within  
58 routine workload, flexible to achieve bona fide scalability (Fig. 1).

59

## 60 **Details of SHANEL method**

61 Clarifying the key challenges during the time-consuming endeavour of human organ  
62 processing is a prerequisite requirement. Here we delineate the main problems that pose to  
63 guide the development of our strategies in Table 1.

64

65 Keeping all these questions in mind, we started with introducing the active perfusion system  
66 to deliver 0.01 M PBS/heparin and 4% PFA solutions into whole organs through vascular  
67 network before the organs harvest if resources are accessible (Fig. 2, Supplementary Fig.  
68 1a). The advantages of this step included washing out remaining blood as much as possible,  
69 circulating the vascular system before the forming of clots and faster tissue fixation than  
70 passive immersion. The organs were dissected carefully to preserve intact anatomical  
71 shapes and connect the main arteries with exogenous tubes for later experiments.  
72 Otherwise, human samples could be passively fixed in 4% PFA or 10% formalin buffer to  
73 covalently crosslink the proteins. It is worth mentioning that human organ and tissue donation  
74 organizations such as IIAM (international institute for the advancement of medicine) are  
75 reliable resources, which provide transplantable organs with intact vascular systems and  
76 detailed donor information.

77

78 Among the hydrophilic reagent-based<sup>21-24</sup>, hydrogel-embedding<sup>19,25-27</sup>, hydrophobic reagent-  
79 based<sup>9,10,13,14</sup> tissue clearing methods, we chose to work with hydrophobic reagents for tissue  
80 clearing steps in the SHANEL pipeline. An important advantage of hydrophobic tissue  
81 clearing is sample shrinkage, enabling us to accommodate and image large organs using a  
82 light sheet fluorescent microscope. Ethanol was employed to get rid of the water inside of  
83 human tissue, by increasing serial ethanol concentration step wisely. Dichloromethane was  
84 used to extract the remaining lipid and ethanol, after which the tissue was mostly composed  
85 of fixed proteins. In the end, the relatively homogenous human tissue became transparent by  
86 immersing it into the BABB solution (benzyl benzoate: benzyl alcohol= 2:1, v/v) with a  
87 refractive index of 1.56, the same as that of the cross-linked proteins. In general, the  
88 hydrophobic reagents cleared organs will shrink ~30% in volume<sup>10,20</sup>. However, traditional  
89 commercialized LaVision UltraMicroscope II system (chamber size of 72 x 74 x 35 mm,  
90 sample traveling range of 10 x 10 x 10 mm in X,Y,Z) or ZEISS Lightsheet 7 (sample size of

91 10 x 10 x 20 mm) cannot hold the large cleared human organs, such as an intact eye (size of  
92 30 x 30 x 30 mm). We co-designed together with Miltenyi Biotec and developed a prototype  
93 UltraMicroscope (chamber size of 250 x 90 x 70 mm) (Fig. 3). Then Miltenyi Biotec releases  
94 commercialized as UltraMicroscope Blaze (chamber size of 129 x 51 x 64 mm, sample travel  
95 range of 50 x 24 x 23 mm), fully automated light-sheet microscopes for imaging large cleared  
96 samples covering the range from entire mice to most human organs.

97

98 Efforts to label and clear human brain pieces by screening with thousands of chemicals<sup>28</sup> or  
99 employing extra forces<sup>17,19</sup> have already shown the difficulties regarding to incomplete tissue  
100 transparency, time-consuming procedures and limited antibody penetration. Given that aged  
101 human tissue is composed of dense and intricate hydrophobic and hydrophilic molecules, we  
102 hypothesized that an efficient detergent permeabilization is necessary to render the human  
103 tissue accessible to reagents traveling end-to-end through it. Detergents are amphiphilic,  
104 possessing both hydrophilic and hydrophobic properties, and forming micelles in solutions  
105 that can interact with molecules of the tissue. Traditional detergents of ionic SDS (Sodium  
106 dodecyl sulfate) or non-ionic Triton X-100 (4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene  
107 glycol), carrying typical 'head-to-tail' chemical structures, are inefficient at permeabilizing the  
108 sturdy human tissues because their micelle sizes are too big to enter deeply inside of tissue.  
109 We identified CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) as a  
110 powerful candidate to completely and quickly permeabilize intact human organs, as it forms  
111 much smaller micelles with its special 'facial' chemical structure. CHAPS ameliorates the  
112 microenvironments of cellular and extracellular matrix of aged human tissue to make the  
113 intact human organs permeable and accessible by reagents. To remove the red colour of  
114 remaining blood clots, we screened diverse heme-eluting chemical analogues that are  
115 compatible with CHAPS. Analogues bearing ethanolamine structures have improved  
116 decolorization effects in the presence of CHAPS<sup>20</sup>. Although potential candidates such as N-  
117 Butyldiethanolamine<sup>28</sup> and N,N,N',N'-tetrakis(2-hydroxypropyl)ethylenediamine (Quadrol)<sup>24</sup>  
118 have been proved to be efficient in decolorizing, but they are at least 2 times more expensive  
119 than N-methyldiethanolamine (NMDEA) (~30 €/ liter). Considering the intact human organs  
120 consume a large amount of decolorization chemical agents, we decided to use a NMDEA  
121 and CHAPS mixture to achieve the permeabilization and decolorization to reduce the cost.  
122 Still, the volume of the reagents consumed in a single step of handling an intact human brain  
123 was around 5-6 L, and the total cost of all chemicals was about 3200 Euro<sup>20</sup>.

124

125 Small molecular dyes (<1-2 kDa) or large molecular antibodies (~150 kDa) provide  
126 fluorescent contrast of signal-to-background to identify specific structures of human tissue.  
127 DNA or RNA chemical probes show high binding specificities and affinities to the nucleic acid  
128 of cells across a wide range of fluorescent spectra (e.g. DAPI, Hoechst in blue-green range;  
129 JO-PRO-1, PI in green-red range; TO-PRO3, SIR in red range)<sup>29</sup>. Furthermore, chemical  
130 fluorochromes conjugated primary or secondary antibodies cannot penetrate and label more  
131 than **1 cm** deep into the **adult** human organ due to their big sizes. Hence, we introduced  
132 chemical pre-treatments to loosen the cellular and extracellular matrix. First, a solvent  
133 mixture of dichloromethane/methanol (2:1, v/v) was used to extract the hydrophobic lipids  
134 inside the tissue which would repeal the free movement of hydrophilic labelling reagents  
135 dissolved in buffer<sup>30</sup>. Second, the tissue was subjected to acetic acid for partial hydrolysis of  
136 intertwined collagen by cleavage of the non-covalent intra- and inter-molecular bonds<sup>31</sup>. This  
137 process maintains the collagen chains intact, but the cross-links are cleaved. Third,  
138 guanidine hydrochloride buffer was employed to extract the proteoglycans of tissue in

139 dissociative conditions<sup>32</sup>. After these chemical extraction steps, the spatial interval of tissue  
140 matrix became accessible to both small molecular dyes and large molecular antibodies at a  
141 depth range centimetres. Cell nuclei in intact human pancreas were perfused and labelled  
142 with PI (Fig. 4). Vasculature in multiple human organs was labelled with dextran solution (Fig.  
143 5). SHANEL is also compatible with passive incubation of dye and antibodies to stain PFA  
144 fixed human tissue up to centimetres size range (Fig. 6). As we have previously  
145 demonstrated, 1.5 cm cubic human brain pieces were successfully labelled with primary  
146 antibody and secondary antibody for cellular (e.g. Iba1) and molecular (e.g. tyrosine  
147 hydroxylase) structures<sup>20</sup>. Eventually, antibody conjugated with large protein dyes (e.g.  
148 phycoerythrin) also fully labelled more than 1 cm cubic human kidney and lung pieces to  
149 present cytoplasmic (e.g. Catalase), extracellular (e.g. Collagen IV), and membranous (e.g.  
150 cytokeratin 19) structures of tissue (Supplementary Fig. 2 and Table 2).

151  
152 With the prototype or commercial UltraMicroscope Blaze, it is possible to scan the intact  
153 human eye, kidney, thyroid and pancreas by mosaic imaging. The scanning time depends on  
154 the size of the sample, the overlapping percentage of the mosaic, the number of scanning  
155 channels and the settings of the Z step (Supplementary Fig. 3). Correspondingly, terabytes  
156 of large data can be generated from a single organ. Software such as Fiji, Arivis, Imaris and  
157 Photoshop can be used to handle the large data for 3D reconstruction and movie generation  
158 with a standard lab workstation (e.g., > 256 gigabytes of RAM and terabytes of storage  
159 space) (Supplementary Fig. 4-6). However, quantitative analysis of such large data can be  
160 difficult and imprecise using such software, which in general relies on simple strategies such  
161 as filter-based normalization, thresholding or watershed algorithms. Recently, deep learning  
162 approaches<sup>14,20,33</sup> have shown superior performances in quantification of large-scale data in  
163 terms of processing accuracy and speed. It is anticipated that 3D human organ mapping  
164 could be greatly advanced with a full exploitation of combining tissue clearing and imaging with  
165 deep learning technologies.

166

### 167 **Adaptive applications of SHANEL**

168 Mammalian skeletal bones shelter diverse special physiological dynamics and functions  
169 across the whole body system. An expanding exploration of deep tissue labelling, clearing  
170 and imaging of bones using SHANEL would greatly benefit to investigate the 3D geometric  
171 features of bone volume and cells. In addition to the soft tissues such as bone marrow,  
172 bones contain hard mineral-dense regions that are deposited with calcium-bearing  
173 hydroxyapatite crystals in collagen matrix. The calcium content considerably induces optical  
174 scattering of bone<sup>34</sup>. EDTA has been demonstrated as an efficient decalcification reagent in  
175 previous studies<sup>35,36</sup>. Similarly, Tainaka et al developed a carbonated hydroxyapatite-based  
176 screening system to identify potent decalcification chemicals compatible with the tissue  
177 clearing and found EDTA combining with imidazole showed superior effects<sup>28</sup>. Hence, we  
178 conducted decalcification of bones using 20% EDTA at 37°C before SHANEL tissue labelling  
179 and clearing, as shown with examples of human skull pieces and pulvinar soft tissue inside  
180 the joint cartilage surface surrounded by bones (Fig. 7). Human bone samples are much  
181 thicker and harder than mouse ones, which would take much longer time to achieve the  
182 desired softness, in the range of weeks to months. There are alternative decalcification  
183 reagents composed by strong, mild or weak acids (e.g. nitric acid, formic acid, hydrochloric  
184 acid, chromic acid etc.). It is claimed that 5% nitric acid is an option for rapid decalcification  
185 while yielding acceptable tissue integrity and antigenicity<sup>37,38</sup>.

186



187 SHANEL tissue clearing methods have been proven to be applicable to other mammalian  
188 species such as pig brain, pig pancreas and be compatible with vDISCO immunostaining<sup>20</sup>.  
189 This would enable imaging large mammalian organs that are expressing fluorescent proteins  
190 such as GFP, YFP, mCherry, and tdTomato. Since fluorescent protein labeling of cells are  
191 widely used including in zebrafish, rat, mouse, pig, and macaque, SHANEL can readily be  
192 adopted to clear and image diverse organisms. In such a case, the organs are first, actively  
193 perfused or passively incubated with the mixture of CHAPS and NMDEA to permeabilize and  
194 decolorize tissue. Afterwards, vDISCO immunostaining process is used via  
195 perfusion/incubation with the chosen nanobody in a solution of 1.5 vol% goat serum, 0.5  
196 vol% Triton X-100, 0.5 mM of methyl- $\beta$ -cyclodextrin, 0.2 wt/vol% trans-1-acetyl-4-hydroxy-L-  
197 proline and 0.05 wt/vol% sodium azide in PBS. Finally, the organs become ready to clear by  
198 SHANEL reagents. It is anticipated that after CHAPS and NMDEA treatment,  
199 nanobody/antibody immunolabeling and SHANEL tissue clearing could be applied to diverse  
200 mammalian species to investigate broad biological questions. In cases where antibody-  
201 based tissue labelling fails due to its size-limited inability to cross through whole organs, ten  
202 times smaller nanobodies could provide a more viable alternative.

203  
204 Although the SHANEL tissue labelling and clearing method is developed for intact human  
205 organs, it also works for small tissue pieces, for example on human biopsies. In general,  
206 biopsy samples are small in size and suitable for the application of the passive SHANEL  
207 labelling and clearing method.

208

### 209 **Comparison with other methods**

210 In the last years, researchers reported their works of labelling and clearing of human organ  
211 pieces by diverse methods including CLARITY<sup>17,39</sup>, OPTIClear<sup>16</sup>, MASH<sup>18</sup>, CUBIC<sup>28</sup>,  
212 SWITCH<sup>40</sup>, SHIELD<sup>11</sup> and ELAST<sup>19</sup>. CLARITY and OPTIClear took months to clear fixed  
213 human brain tissue pieces (<5 mm thickness). MASH explored the small-molecule  
214 fluorescent dye labelling and clearing of human brain cortex (< 5 mm thickness) by modifying  
215 the iDISCO protocol. Other methods were applicable to 3D imaging of human myocardial  
216 tissue<sup>41</sup>, lymph node and lung pieces (< 1cm<sup>3</sup>)<sup>42</sup>. SWITCH allowed multiple rounds of  
217 antibody labelling in 100  $\mu$ m thick human brain section. Based on SWITCH method, SHIELD  
218 used tissue transformation strategy to stabilize 2 mm thick human brain slice via  
219 intramolecular epoxide linkages to prevent degradation. ELAST enabled human brain tissue  
220 (< 5 mm thickness) antibody labelling and clearing by mechanically stretching tissue-  
221 hydrogel hybrids. The key step of the SHANEL technology relied on the permeabilization and  
222 decolorization by CHAPS/NMDEA solution.

223  
224 For the first time, SHANEL technology achieved the labelling and clearing of intact adult  
225 mammalian organs of centimetres sizes, including human brain, pig brain, pig pancreas,  
226 human kidney, human thyroid<sup>20</sup>, human heart, human pancreas, human lung and spleen (Fig.  
227 5). The whole process can be conducted by passive incubation or active perfusion,  
228 depending on the availability of main vessels for external connection to commercialized  
229 pumps. This could scale up the process to numbers of organs, with simple set-up in standard  
230 labs, and no special expertise or training required to implement. It is preferred to perform  
231 active perfusion for large adult organs, in order to speed up the process to a reasonable  
232 period (e.g. 1.5 months for human kidney, 4 months for human brain). The timeline for each  
233 step varies case by case depending on the specific organs. Even a pair of kidneys from the  
234 same donor could be different in size, hardness, blood clots and pigments accumulation. The

235 organs should be assured to completely fulfil the target of each step of permeabilization and  
236 decolorization, delipidation, cellular and extracellular matrix loosening and labelling,  
237 dehydration and refractive index matching.

238

### 239 **Experimental design**

240 SHANEL provides a flexible platform for diverse human organ resources to achieve whole or  
241 partial organ labelling, clearing, and imaging at a cellular level (Fig.1, Supplementary Fig. 7).  
242 The whole pipeline is focused on the main steps: (i) preparation of fixed organs according to  
243 the donor (steps 1-2); (ii) sample pre-treatment, including optional steps such as  
244 decalcification and blood vessel labelling (steps 3-7); (iii) labelling with chemical probes or  
245 antibodies (steps 8-14); and (iv) tissue clearing and imaging with light-sheet microscopy  
246 (steps 15-17).

247

### 248 **Expertise needed to implement the protocol**

249 We would recommend people with knowledge from the biological, medical, or human  
250 anatomical background or with previous experience in handling commercial light-  
251 sheet microscopes to implement this protocol. With the skills of using Fiji, Imaris, and  
252 Arivis software, it will be more quickly to master this method.

253

### 254 **Limitations of the current SHANEL pipeline**

255 As most of the tissue clearing methods, the SHANEL tissue labelling and clearing protocol  
256 includes the delipidation step, which cannot be compatible with fluorescent lipophilic dyes,  
257 such as Dil. One possibility is using modified Dil-analogues, for example CM-Dil, SP-Dil or  
258 FM 1-43FX, that could be covalently attached to tissue proteins during aldehyde-fixation.  
259 These dyes would adhere to the cellular membranes and proteins, even after lipid clearing<sup>43</sup>.

260

261 Another issue that we have to take into consideration is the fact that blood clots and  
262 lipofuscin cause strong autofluorescence in human samples. The accumulation of lipofuscin  
263 is associated with the process of ageing<sup>44</sup>. Its presence would complicate the analyses of  
264 specific fluorescence labelling. It has been reported to reduce or eliminate autofluorescence,  
265 without adversely affecting the targeted labels, by chemical treatment<sup>45-47</sup> (e.g. CuSO<sub>4</sub>,  
266 Sudan Black B, NaBH<sub>4</sub>) or photobleaching<sup>19</sup>. We found that CuSO<sub>4</sub> was greatly efficient in  
267 reducing the lipofuscin autofluorescence whilst being compatible with labelling. However, due  
268 to the natural blue color of CuSO<sub>4</sub> solution, the sample color could be light blue after  
269 treatment depending on the concentration of CuSO<sub>4</sub> solution, which would partially absorb  
270 the laser light energy used during imaging. Therefore, there is a compromise of fluorescence  
271 signal-to-background ratio when decreasing the autofluorescence signal. In the future, it  
272 would be valuable to identify a colorless, efficient chemical to remove autofluorescence in the  
273 SHANEL protocol.

274

275 Furthermore, an additional necessary step is the validation of new antibodies, nanobodies or  
276 dyes before their application within large organs. Human organs have to be pre-treated with  
277 diverse chemicals to loosen the extracellular matrix to allow the antibody or nanobody travel  
278 inside. These chemicals would potentially affect the binding of antibody/nanobody with target  
279 antigen epitopes of human samples. Nevertheless, positive staining after SHANEL method  
280 indicates that the antibody target is well-preserved and specific when comparing the result  
281 with previous traditional immunostaining paper. Abundantly commercialized  
282 antibodies/nanobodies often require rigorous in-house validation. A well-accepted way of

283 quickly selecting an antibody compatible, sensitive, and specific with SHANEL, our  
284 experience is to choose a research antibody that has been listed in the top-cited ranks in a  
285 searchable antibody database<sup>48</sup>. Commonly, human samples firstly go through all pre-  
286 treatment steps of CHAPS/NMDEA, delipidation and ECM loosening in SHANEL, then  
287 samples were subjected to traditional slicing technique (e.g. cryostat) to generate lots of thin  
288 sections (e.g. 10-50  $\mu\text{m}$ ). With these sections, the product lot, optimized working  
289 concentration and staining conditions were identified. An antibody provides a good signal in  
290 tissues sections, which always indicates it has a good chance of being compatible with  
291 SHANEL. As mentioned before, confirmed labelling reagents in the lab were summarized in  
292 Table 2.

293

294 Although the SHANEL tissue labelling and clearing technology is capable to turn human  
295 organs as large as the intact brain transparent, current light-sheet fluorescent microscopy  
296 have a limited capacity to image all big human organs. In addition, especially for volumetric  
297 imaging of whole organs with long-working distance objectives, the current commercial light-  
298 sheet microscopes face the problem of poor resolutions in Z, which lead to inevitable non-  
299 isotropic volumetric images. In general, whole organ imaging reconstruction data got less  
300 influence of non-isotropic volumetric images by quantitative analysis of mesoscale structure.  
301 Light-sheet microscope such as MesoSPIM is integrated with a moving-waist beam and can  
302 improve the resolution, especially in the Z dimension<sup>49</sup>. The SHANEL method didn't include  
303 eliminating the signal from the antibodies stained, and we didn't try the multiple rounds of  
304 antibodies relabeling. Efforts on optimized SHANEL method for multiple round labelling of  
305 antibodies will also be made.

306

## 307 **Materials**

### 308 **Human organ materials**

309 All human organs were taken from different human body donors. All donors gave their  
310 informed and written consent to explore their cadavers for research and educational  
311 purposes, when still alive and well. The signed consents are kept at the Anatomy Institute,  
312 University of Leipzig, Germany. Institutional approval was obtained in accordance to the  
313 Saxonian Death and Funeral Act of 1994. The signed body donor consents are available on  
314 request.

- 315 • Human kidney, pancreas, pulvinar and human brain with skull were dissected from an  
316 88-year-old female donor.
- 317 • Human heart, lung, spleen and pancreas for vessel labelling were from a 79-year-old  
318 female donor.
- 319 • Brain slices for immunolabeling were from an 86-year-old female. Lung and kidney  
320 tissue for immunolabeling were from a 97-year-old female donor.

321

### 322 **Reagents**

- 323 • 1x Phosphate-buffered Saline (PBS) (diluted from 0.1 M stock solution, Apotheke  
324 Klinikum der Universität Munchen, cat. no. P32799)
- 325 • Deionized water (diH<sub>2</sub>O, in house purification system)
- 326 • 4% PFA in 1x PBS solution (4 wt/vol%; pH 7.4, Morphisto, cat. no. 11762.01000)  
327 **!CAUTION** Toxic reagent. **▲CRITICAL** store at 4°C and do not use it when expired.
- 328 • Heparin (Braun, 25000 IE/5ml)
- 329 • Tetramethylrhodamine isothiocyanate–Dextran (mw 500000, Sigma-Aldrich, cat.  
330 no.52194)
- 331 • p-maleimidophenyl isocyanate (PMPI) (ThermoFisher, cat. no. 28100) **!CAUTION**  
332 Eye and skin irritation.
- 333 • Dithiothreitol (DTT) (Sigma-Aldrich, cat. no.43815) **!CAUTION** Eye, skin and  
334 respiratory irritation.
- 335 • Propidium Iodide (PI) (ThermoFisher, cat. no. P1304MP)
- 336 • 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) (Carl Roth,  
337 cat. no.1479.4) **!CAUTION** Light powder, avoid inhalation. **▲CRITICAL** store at 4°C  
338 and do not use it when expired.
- 339 • N-methyldiethanolamine (NMDEA) (Sigma-Aldrich, cat. no.471828) **!CAUTION** Eye  
340 irritation.
- 341 • Guanidine hydrochloride (Carl Roth, cat. no. 6069.3) **!CAUTION** Skin and eye  
342 irritation.
- 343 • Acetic acid (Carl Roth, cat. no. T179.1) **!CAUTION** Danger of flammable and  
344 corrosive. Skin and eye damage.
- 345 • Sodium acetate (Sigma-Aldrich, cat. no. S2889) **▲CRITICAL** Storage separated from  
346 strong acids and strong oxidants.
- 347 • Triton X-100 (PanReac Applichem, cat. no. A4975,1000) **!CAUTION** Danger of  
348 corrosive, irritant and environmental hazard. Skin and eye damage.
- 349 • 2-Hydroxypropyl-beta-cyclodextrin (HPCD, PanReac Applichem, cat. no.  
350 A0367,0100)
- 351 • DMSO (Carl Roth, cat. no. A994.2) **!CAUTION** skin and eye irritation.
- 352 • NaOH (Carl Roth, cat. no. 6771.1) **!CAUTION** Danger of corrosive. Skin and eye  
353 damage.

- 354 • Ethanol (Merck, cat. no. 10098535000) **!CAUTION** Danger of flammable.
- 355 • Methanol (Carl Roth, cat. no. 4627.6) **!CAUTION** Danger of flammable, acute toxic
- 356 and health hazard. Toxic reagent.
- 357 • Dichloromethane (DCM, Carl Roth, cat. no. KK47.1) **!CAUTION** Health hazard.
- 358 Evaporate.
- 359 • BABB (benzyl benzoate:benzyl alcohol = 2:1, Sigma-Aldrich, cat. no. W213802, cat.
- 360 no. 24122) **!CAUTION** Irritant and environmental hazard.
- 361 • Sodium azide (Sigma-Aldrich, cat. no. 71290) **!CAUTION** Danger of acute toxic and
- 362 environmental hazard.
- 363 • Goat serum (GIBCO, cat. no. 16210072)
- 364 • Copper sulfate (CuSO<sub>4</sub>, Carl Roth, cat. no. CP86.1)
- 365 • Ammonium chloride (Carl Roth, cat. no. P726.1)
- 366

## 367 **Equipment**

- 368 • Surgery scissors (FST, cat. no. 14958-11)
- 369 • Big Metal Tweezers (FST, cat. no. 11000-20)
- 370 • Fine Metal Tweezers (FST, cat. no. 11252-40)
- 371 • peristaltic pump (ISMATEC, REGLO Digital MS-4/8 ISM 834)
- 372 • PTFE tubing (VWR, 228-0735)
- 373 • Reference tubing for the ISMATEC peristaltic pump (ISMATEC, cat. no. SC0026)
- 374 • Glass chamber (Omnilab, cat. no. 5163279)
- 375 • Glass chamber (LABICAT, cat. no. 40070360, 40070180)
- 376 • Shaking rocker (IKA, 2D digital).
- 377 • Shaker (IKA, model KS 260 basic)
- 378 • 5 ml tubes (Eppendorf, cat. no. 0030 119.401) ▲ **CRITICAL** highly recommend due to
- 379 the resistance to clearing solutions
- 380 • 15 ml tubes (Thermo Fisher Scientific, cat. no. 339651) ▲ **CRITICAL** highly
- 381 recommend due to the resistance to clearing solutions
- 382 • 50 ml tubes (Thermo Fisher Scientific, cat. no. 339653) ▲ **CRITICAL** highly
- 383 recommend due to the resistance to clearing solutions
- 384 • 1 L glass beakers (any, we used the ones from DURAN)
- 385 • 1 L glass bottles (any, we used the ones from DURAN)
- 386 • 2 L glass bottles (any, we used the ones from DURAN)
- 387 • 500 ml glass bottles (any, we used the ones from DURAN)
- 388 • PTFE covered magnetic stirring bars (any)
- 389 • Hot magnetic stirrer (IKA, model RCT basic B-5000, cat no. 0003810000)
- 390 • Aluminium foil (any)
- 391 • Plastic wrap (any)
- 392 • Disposable underpads (Medimex, cat no. E1911804, or any)
- 393 • Syringes of 1 ml, 5 ml, 10 ml, 50 ml (any)
- 394 • Tapes, black and transparent ones (any)
- 395 • Parafilm (Bemis, cat. no. PM-992)
- 396 • pH meter (WTW, model pH7110)
- 397 • Shaking rocker (IKA, model 2D digital)
- 398 • Incubator (Mettler, model UN160), although any incubator that reaches keeps 37°C
- 399 with a shaker inside is fine

- 400 • Fume hood

401

## 402 **Imaging systems**

- 403 • Computer equipped with light-sheet microscope (Processors: Intel Core i7-7800X  
404 CPU @ 3.50GHz; graphic card: NVIDIA Quadro K420; random access memory:  
405 32GB; solid state drive: Samsung SSD 860 PRO 1TB; hard disk drive: Seagate  
406 Enterprise Capacity SATA 12TB (ST12000NM0007); operation system: Windows 10  
407 Pro, 64 bit.)

408

409 Miltenyi Biotec UltraMicroscope II light-sheet microscope coupled with:

- 410 • SuperK EXTREME/FIANIUM supercontinuum white light laser (NKT Photonics, model  
411 SuperK EXTREME EXW-12)
- 412 • Andor sCMOS camera Neo 5.5 (Andor, mod. no DC-152Q-C00-FI)
- 413 • Filter sets: ex 470/40 nm, em 535/50 nm; ex 545/25 nm, em 605/70 nm; ex  
414 560/30 nm, em 609/54 nm; ex 580/25 nm, em 625/30 nm; ex 640/40 nm, em  
415 690/50 nm
- 416 • Olympus MVX10 zoom body (zoom range 0.63x-6.3x)
- 417 • Olympus revolving zoom body unit (U-TVAC)
- 418 • 1x air objective (Olympus MV PLAPO ×1/0.25 NA, WD = 65 mm)
- 419 • 2x immersion objective (Olympus MVPLAPO2XC/0.5 NA, WD = 6 mm)
- 420 • 4x immersion objective (Olympus XLFLUOR ×4 corrected/0.28 NA, WD = 10 mm)
- 421 • 12x immersion objective (Lavisoin MI PLAN 12x /0.53NA, WD = 10mm)
- 422 • 20x immersion objective (Zeiss ×20 Clr Plan-Neofluar/0.1 NA, WD = 5.6 mm)

423

424 Miltenyi Biotec prototype UltraMicroscope light-sheet microscope for large samples coupled  
425 with:

- 426 • LASOS Multi Color System Series for the laser box (LASOS, model MCS5 F2-01)
- 427 • Andor sCMOS camera Zyla 5.5 (Andor, mod. no ZYLA-4.2P-CL10)
- 428 • Filter sets: ex 488 nm, em 525/50 nm; ex 561 nm, em 595/40 nm; ex 640 nm, em  
429 680/30 nm; ex 785 nm, em 845/55 nm
- 430 • Olympus revolving zoom body that can switch between 1x and 2x with an autofocus-  
431 Cube AFC-UM2-UBG
- 432 • 1.1x objective (LaVision MI PLAN x1.1/0.1 NA, WD = 17 mm)

433

434 Zeiss LSM 880 inverted laser-scanning confocal microscope coupled with

- 435 • 25x water-immersion objective (Leica, x25/0.95 NA, WD = 2.5 mm) mounted with a  
436 custom mounting thread.

437

438 ▲ **CRITICAL** Check the compatibility of the microscope and objectives of different brands  
439 with the vendors.

440

## 441 **Computer and Data processing and analysis tools**

- 442 • Computer (HP Z840 workstation; Windows 10 Pro, 64 bit; CPU: Intel Xeon E5-2640  
443 v3; Installed memory: 256GB; GPU: NVIDIA Quadro M5000)
- 444 • Fiji (ImageJ2, <https://fiji.sc/>) for stitching original mosaic tiffs from light-sheet  
445 microscope

- 446 • Total Commander (v. 8.52a x64, <https://www.ghisler.com/>) for rename the file names
- 447 of stitched tiffs
- 448 • ImageMagick (v. 7.0.5-4, <https://imagemagick.org/script/index.php>) for Lempel-Ziv-
- 449 Welch (LZW) TIFF compression
- 450 • Vision4D (v.3.0.1 x64, Arivis) for fusing intact organs from multiple scans
- 451 • Arivis converter (v.2.12.6, Arivis)
- 452 • Imaris (Bitplane) for visualization of 3D images
- 453 • Photoshop CS6 (v. 13.0, Adobe)

454

## 455 **Reagent setup**

### 456 **Dextran vessel labelling solution**

457 Tetramethylrhodamine isothiocyanate–Dextran is a commonly used dye to trace vessels *in*  
458 *vivo*. To chemically fix dextran inside the vessels, we used p-maleimidophenyl isocyanate  
459 (PMPI) and DL-dithiothreitol (DTT) to crosslink the hydroxyl group of dextran to the surround  
460 sulfhydryl-containing proteins. The working solution of dextran is containing 5 mg/ml  
461 tetramethylrhodamine isothiocyanate-dextran, 0.4 mM PMPI and 1 mM DTT in PBS. For  
462 example, as shown in the following table, each reagent is prepared separately. 1) dissolve  
463 8.6 mg PMPI in 2 ml DMSO; 2) dissolve 15.4 mg DTT in 5 ml PBS; 3) dissolve 0.5 g dextran  
464 in 93 ml PBS. Mixing all solutions together before the perfusion. (See Table 3)

465 ▲ **CRITICAL** Prepare fresh solutions before starting the experiment. **!CAUTION** Prepare the  
466 solutions in hood and wear mask.

467

### 468 **EDTA solution**

469 EDTA decalcification solution is prepared with 20% (w/v) EDTA in diH<sub>2</sub>O, adjusting the PH to  
470 8.0-8.5 using NaOH or HCl. For example, in a 2L bottle with stirring bar, dissolve NaOH  
471 continuously to keep 1.5 L diH<sub>2</sub>O alkaline, then slowly add 400 g EDTA powder. Replenish  
472 diH<sub>2</sub>O, more NaOH or HCl until reaching 2L with PH of 8.0-8.5. **!CAUTION** If EDTA  
473 precipitation happens, adding more NaOH until the solution becomes transparent.

474

### 475 **CHAPS/NMDEA solution**

476 CHAPS/NMDEA mixture is composed of 10% (wt/v) CHAPS and 25% (wt/v) NMDEA (N-  
477 methyl-diethanolamine) in diH<sub>2</sub>O. For example, in a 2 L bottle, mix 200 g of CHAPS and 500 g  
478 of NMDEA in diH<sub>2</sub>O with a stirrer at room temperature (22-25 °C) and set the final volume to  
479 2 L. The reagent could be stored at 4 °C for several months. **!CAUTION** CHAPS is a light  
480 powder, it is suggested to wear mask to avoid inhalation during process.

481

### 482 **Acetic Acid solution**

483 Acetic acid solution is 0.5M in diH<sub>2</sub>O. For example, in a 1L bottle, mix 30 mL acetic acid in  
484 diH<sub>2</sub>O at room temperature (22-25 °C) and set the final volume to be 1 L. The reagent could  
485 be stored at room temperature for several months. **!CAUTION** Prepare the solution in hood  
486 and wear mask due to the smell of acetic acid.

487

### 488 **Guanidine solution**

489 Guanidine solution is a mixture of 4 M guanidine hydrochloride, 0.05 M sodium acetate and  
490 2% Triton X-100 in PBS, pH=6.0. For example, in a 2 L bottle, mix 764.2 g guanidine  
491 hydrochloride, 8.2 g sodium acetate and 40 g Triton X-100 in PBS with a stirrer at room  
492 temperature and set the final volume to 2 L. Adjust the PH to 6.0 with 4M NaOH solution and



493 30% hydrochloric acid solution. The reagent could be stored at room temperature for several  
494 months.

495

#### 496 **Dehydration and rehydration solutions**

497 A series of dehydration solutions are prepared by mixing ethanol with diH<sub>2</sub>O for 50%, 70%,  
498 100% (v/v). It is suggested to prepare the solutions in fresh before using.

499

#### 500 **Delipidation solutions**

501 The delipidation solution could be DCM/MeOH mixture or pure DCM solution. For tissue pre-  
502 treatment before labelling, it is mixture of 2 volume of DCM and 1 volume of MeOH. For  
503 tissue clearing after labelling, pure DCM is used. **!CAUTION** DCM is health hazard and  
504 highly volatile. It should be handled in a fume hood by wearing safety goggles and double  
505 layer nitrile gloves to avoid inhalation and contact with skin/eyes. **▲CRITICAL** Prepare fresh  
506 solution before using it.

507

#### 508 **Sodium Azide stock solution**

509 The concentration of sodium azide stock solution is 0.05% (wt/v) dissolving into 1x PBS. This  
510 solution can be stored at 4 °C for several months. **!CAUTION** Avoid contact with skin and  
511 eyes.

512

#### 513 **Blocking buffer for antibody staining**

514 The blocking buffer contains 0.2% (v/v) Triton X-100, 10% (v/v) DMSO and 10% (v/v) goat  
515 serum in 1x PBS. For example, in a 500 ml bottle, mix 1 ml Triton X-100, 50 ml DMSO and  
516 50 ml goat serum in PBS with a stirrer at room temperature. **▲CRITICAL** Prepare fresh  
517 solution before using it. The pre-treated tissue samples could be stored in blocking buffer at  
518 4 °C if adding 0.01% (w/v) sodium azide for several weeks before antibody staining.

519

#### 520 **Antibody incubation buffer**

521 The antibody incubation buffer could be composed by 3% (v/v) goat serum, 3% (v/v) DMSO,  
522 0.2% (v/v) Tween-20 and 10 mg/L Heparin in 1x PBS or by 10% (w/v) HPCD, 3% (v/v) goat  
523 serum and 10 mg/L Heparin if the antibody water-solubility is poor. **▲CRITICAL** Prepare  
524 fresh solution before using it.

525

#### 526 **Antibody washing buffer**

527 The antibody washing buffer is prepared by 0.2% (v/v) Tween-20 and 10 mg/L Heparin in 1x  
528 PBS. This solution can be stored at 4 °C for several months.

529

#### 530 **Copper sulphate (CuSO<sub>4</sub>) solution**

531 The copper sulfate solution can be used to eliminate tissue autofluorescence. Dissolve 1.6 g  
532 CuSO<sub>4</sub> and 2.67 g ammonium chloride in diH<sub>2</sub>O, adjust pH to 5.0 and set the final volume to  
533 1 L.

534

#### 535 **RI matching solution**

536 BABB is the RI matching solution, which is composed by benzyl alcohol and benzyl benzoate  
537 with a ratio of 1:2 in volume. BABB solution should be prepared and stored within glass  
538 container at room temperature in a fume hood. **!CAUTION** Benzyl benzoate is harmful if  
539 swallowed, and cause skin and eye irritation. Benzyl alcohol is harmful if swallowed and  
540 inhaled. In hence, handling must be operated by wearing safety goggles, nitrile gloves  
541 (preferably double layer) and lab coats.

542

## 543 **Equipment setup**

### 544 **Pump system**

545 In active perfusion system, the setting-up are constituted by an Ismatec peristaltic pump and  
546 connected tubes. This pump allows four channels as needed (Fig. 2, Supplementary Fig. 1).

547

## 548 **Procedure**

### 549 **Preparation of fixed human organs ● Timing 1-2 d**

- 550 1. Human organs perfusion with PBS/heparin and PFA fixation.
- 551 i. According to the anatomy characteristic of the human organs, use diameter  
552 size-matched plastic tubes stitching in the opened arteries and veins.  
553 **!CAUTION** Identify any risk factors for acute transmission before human  
554 organ handling.
- 555 ii. At room temperature, using a gravitation irrigator system sets up the irrigator  
556 height as 0.5m to perfuse the human organs. Marker the start level of  
557 PBS/heparin (2.5U heparin per milliliter) solution of the irrigator and perfuse  
558 via the plastic tubes with PBS/heparin solution for 3-5 hours until the blood is  
559 flushed out with the sign of specimens changed their color to bright. It takes  
560 50 liters of such PBS/heparin solution for a heart-lung block and 20 liters for  
561 smaller organs such as kidneys, spleens, or brains.
- 562 iii. Switch the PBS/heparin solution and continue to perfuse with 4% PFA solution  
563 for 15 minutes. Control the perfusion speed by setting up the irrigator height  
564 as 0.5m. It takes 20 liters per lung/hearth block and 10 liters for the kidneys,  
565 spleens, or brains. **!CAUTION** If there was no noticeable flow from the human  
566 organs, lift the irrigator to increase the perfusion speed (maximal 1.2 m height).  
567 A fume hood is necessary when working with formalin solution, which is toxic  
568 with a strong, pungent odor.
- 569 iv. Post-fix the human organs with a 10 times volume 4% PFA solution for 7  
570 days. **!CAUTION** The duration of fixation can affect sample integrity. Optimal  
571 fixing conditions should be assessed for each organ and tissue to prevent  
572 underfixation or overfixation.

- 573 2. Wash the PFA-fixed human organ for following experiments.

574 If perfusion applicable, under a fume hood, set up the pump perfusion system with  
575 connecting tubing on a layer of disposable pads. Put PFA fixed human organs in a  
576 proper glass container and actively perfuse with enough PBS at room temperature for  
577 at least three times. The speed of pump is 45-46 rpm (160–170 mmHg), and flow rate  
578 is 12.5 ml/min. If not applicable, under a fume hood, put a layer of disposable pads on  
579 the shaker. Put PFA fixed human organs in a proper glass container or falcons and  
580 passively incubate with enough PBS at room temperature at least three times. The  
581 speed of shaker is 50 rpm.

582 **!CAUTION** The connect points of tubing can be protected or sealed with parafilm  
583 if needed.

584 ■ **PAUSE POINT** The fixed human organs could be stored at 4 °C in PBS with  
585 0.01% (wt/vol) sodium azide.

586

### 587 **Organ pre-treatment according to experimental needs ● Timing 1-14 d**

- 588 3. In this step, we use different methods to treat different kind of human organs. If the  
589 organ vasculature is well preserved, we can perfuse it with dextran vessel labelling

590 solution. EDTA decalcification is needed in case there is bone tissue to be labelled  
591 and cleared.

592 (A) **Vessel labelling with dextran by perfusion (optional)** ● **Timing 1 d**  
593 (Figure. 2)

594 i. Set up the pump perfusion system with connecting tubing on a layer of  
595 disposable pads. Put human organ in an empty and clean glass  
596 container, then perfuse it with fresh dextran working solution through  
597 each of the organ-inserted tubing until the solution is leaking out, which  
598 means the full filling of dextran solution. The speed of pump is 45-46  
599 rpm (160–170 mmHg), and flow rate is 12.5 ml/min. The leaking  
600 solution can be collected in a container and reused for another round  
601 of perfusion labelling.

602 ▲ **CRITICAL** Ensure the organ turn red after dextran injection

603 ii. After completing vessel labelling, wash the surface of human organ  
604 with running water to get rid of the unspecific contaminations from the  
605 leaking solution. **!CAUTION** If there is extra dye solution coming out  
606 from organ, wipe dry with paper to keep the whole organ surface clean  
607 from dye solution.

608 iii. Put the labelled human organ in a plastic bag and seal with tape.

609 iv. Put the plastic bag with labelled organ in a container and put them in  
610 37 °C incubator overnight.

611 v. Take the human organ out and put it into enough PBS at room  
612 temperature for washing.

613 ? **TROUBLESHOOTING**

614 (B) **Decalcification with EDTA (optional)** ● **Timing 7-20 d**

615 Incubate human organs with bone tissue in 20% (wt/vol) EDTA (PH ≈ 8.0)  
616 with 0.01% (wt/vol) sodium azide solutions at 37 °C. Refresh the solution  
617 every 3-5 days until the bone part gets soft, then wash with PBS.

618 **!CAUTION** EDTA crystals could be precipitated if not sealing well.

619

620 **Permeabilization and decolorization with CHAPS/NMDEA** ● **Timing 3-20 d**

621 4. If perfusion applicable, continue same pump perfusion system with enough  
622 CHAPS/NMDEA solutions to cover the organ for days-month at room temperature,  
623 refresh the solution when the solution get green or dark green colour for 2-3 times,  
624 until the solution does not change colour anymore. The glass chamber is covered  
625 with plastic wrap and aluminium foil to avoid the evaporation of water and light  
626 illumination under fume hood (Supplementary Fig. 1c-d).

627 ? **TROUBLESHOOTING**

628 5. If not applicable with perfusion, continue with the passive incubation on the shaker.  
629 Incubate the organs with enough CHAPS/NMDEA solutions to cover the organ for  
630 days at 37 °C, refresh the solution when the solution get green or dark green colour  
631 for 2-3 times, until the solution does not change colour anymore.

632 **!CAUTION** The reference tubing should be displaced back and forth to different  
633 sever-sections every 2 days to avoid the laxation or clamminess after long-term  
634 non-stopping abrasion. Check the tubing quality carefully time to time, it  
635 happened that the perfusion solution leaked from the wound of tubing if there was  
636 accumulation of abrasion from continuous pump running, especially during the

637 evening time without inspection. The disposable pads were helpful and easy for  
638 cleaning up when leaking accident happened.  
639

640 **Delipidation ● Timing 7-50 d**

641 6. At room temperature, under the fume hood, if perfusion applicable, continue with  
642 same pump perfusion system, if not applicable, continue with the passive incubation  
643 on the shaker.

644 **? TROUBLESHOOTING**

- 645 i. PBS wash twice in 1 day.
- 646 ii. Dehydrate with 50% EtOH/H<sub>2</sub>O solution for 1-7 days.
- 647 iii. Dehydrate with 70% EtOH/H<sub>2</sub>O solution for 1-7 days.
- 648 iv. Dehydrate with 100% EtOH solution for 1-7 days.
- 649 v. Dehydrate with 100% EtOH solution for 1-7 days, until the organ does not  
650 shrink anymore.
- 651 vi. Delipidate with DCM/MeOH (2:1, v/v) solution for 1-7 days, refresh the  
652 solution 2-3 times.
- 653 vii. Rehydrate with 100% EtOH solution for 1-7 days.
- 654 viii. Rehydrate with 70% EtOH/H<sub>2</sub>O solution for 1-7 days.
- 655 ix. Rehydrate with 50% EtOH/H<sub>2</sub>O solution for 1-7 days.
- 656 x. Rehydrate with diH<sub>2</sub>O for 1-7 days.

657 **!CAUTION** The glass chamber should be covered with plastic wrap and aluminium  
658 foil to avoid the evaporation of solution and light illumination under fume hood. EtOH,  
659 MeOH or DCM is highly volatile liquid, especially under the fume hood. The chamber  
660 should be carefully sealed with several layers of plastic wrap and tapes to prevent the  
661 volatility of solutions. Replenish the desired solutions to cover the whole sample if  
662 needed during the circulation. DCM could erode some types of tubing (e.g.  
663 polystyrene), therefore the recommended tubing is from PTFE  
664 (polytetrafluoroethylene) or PP (polypropylene). Displace the reference tubing every 2  
665 days.  
666

667 **ECM loosen ● Timing 2-15 d**

668 7. At room temperature, under the fume hood, if perfusion applicable, continue same  
669 pump perfusion system, if not applicable, continue with the passive incubation on the  
670 shaker.

671 **? TROUBLESHOOTING**

- 672 i. Collagen hydrolysis with acetic acid solution for 1-7 days.
- 673 ii. DiH<sub>2</sub>O wash twice in 1 day.
- 674 iii. Glycoprotein extraction with guanidine solution for 1-7 days.

675 **!CAUTION** The glass chamber should be covered with plastic wrap and aluminium  
676 foil to avoid the evaporation of solution and light illumination under fume hood.  
677

678 **Labelling (optional) ● Timing 7-15 d**

679 If perfusion is applicable, continue same pump perfusion system, if not applicable, continue  
680 with the passive incubation on the shaker. The whole organ can be stained with cell nuclei  
681 dye of PI or TO-PRO-3 solution in PBS (1:1000 dilution) at room temperature for 2-7 days,  
682 the solution should cover the whole organ.  
683

684 If antibody staining is needed, the organ of interest should be tested for certain antibody in  
685 sections first (validated antibody list in Table 2, and non-compatible antibody list in  
686 Supplementary Table 1). **!CAUTION** Antibody is macromolecule, if perfusion is not  
687 applicable, big organs should be dissected into no more than 1.5 cm thick sections to reach  
688 antibody full penetration. Actively pumped antibody solutions to stain intact human organ  
689 have not yet been tested, while Nanobodies have been proven to stain intact pig organs in  
690 active pumping set up.

- 691 8. Sample preparation for antibody/dye/nanobody screening: parts of the targeted tissue  
692 could be sliced to 40  $\mu\text{m}$  thin sections on glass slides by Cryostat following the  
693 standard protocol or cut into 0.3-1 mm floating slices by vibratome following standard  
694 protocol. These sections on glass or floating slices could be used for antibody  
695 screening.
- 696 9. SHANEL pre-treatment for antibody screening: At room temperature, treat the floating  
697 slices with CHAPS/NMEDA solution twice per 12 hours. Wash three times with PBS  
698 for 20 min each. Gradually dehydrate in 50%, 70% and 100% EtOH/H<sub>2</sub>O, 2 hours per  
699 step. Change to DCM/MeOH (2:1, v/v) solution overnight. Rehydrate in 100%, 70%,  
700 50% EtOH/H<sub>2</sub>O and diH<sub>2</sub>O, 2 hours per step. Treat with acetic acid solution overnight,  
701 wash twice for 20 min in diH<sub>2</sub>O, treat with guanidine solution for 6 hours and wash  
702 twice for 20 min in diH<sub>2</sub>O.
- 703 10. These floating slices are blocked with blocking buffer at 37 °C for overnight, then  
704 incubated with commercialized antibodies in antibody incubation buffer at 37 °C for 2  
705 days.
- 706 11. The concentration of antibody should be tested according to the manufactures'  
707 suggestions. If needed, repeat the incubation with proper secondary antibody at 37  
708 °C for 2 days. The samples are washed with washing buffer three times for 1 hour at  
709 room temperature.
- 710 12. Gradually dehydrate in 50%, 70% and 100% EtOH/H<sub>2</sub>O, 2 hours per step. Change to  
711 DCM for 1 hour and then change to BABB until the slice get transparent.
- 712 13. Lastly, the results are examined with confocal microscope to find the best conditions  
713 for strong and specific antibody staining.
- 714 **▲ CRITICAL** We strongly suggest using Alexa dye or Atto dye as conjugated  
715 fluorophores of antibody, which is stable and bright in clearing solution.
- 716 14. After getting the optimistic staining results from antibody screening, dissect the region  
717 of interest from the human organ and treat the tissue slice or block following the  
718 timing in Table 4.
- 719 **! OPTIONAL** Autofluorescent lipofuscin accumulated in aged human sample, incubate  
720 the slice with CuSO<sub>4</sub> solution for 1-7 days before clearing to eliminate tissue  
721 autofluorescence.

#### 722 **? TROUBLESHOOTING**

#### 724 **Clearing ● Timing 7-40 d**

- 725 15. At room temperature, under the fume hood, if perfusion applicable, continue same  
726 pump perfusion system, if not applicable, continue with the passive incubation on the  
727 shaker. **? TROUBLESHOOTING**
  - 728 i. PBS wash twice.
  - 729 ii. Dehydrate with 50% EtOH/H<sub>2</sub>O solution for 1-7 days.
  - 730 iii. Dehydrate with 70% EtOH/H<sub>2</sub>O solution for 1-7 days.
  - 731 iv. Dehydrate with 100% EtOH solution for 1-7 days.

- 732 v. Dehydrate with 100% EtOH solution for 1-7 days, until the organ does not  
733 shrink anymore.
- 734 vi. Delipidate with DCM solution for 1-7 days, until the sample sink to bottom.
- 735 vii. RI matching with BABB solution for 1-30 days until the organ get completely  
736 transparent.

737 **!CAUTION** The glass chamber should be covered with plastic wrap and aluminium foil to  
738 avoid the evaporation of solution and light illumination under fume hood. EtOH or DCM is  
739 highly volatile liquid, especially under the fume hood. The chamber should be carefully  
740 sealed with several layers of plastic wrap and tapes to prevent the volatility of solutions.  
741 Replenish the desired solutions to cover the whole sample if needed during the circulation.  
742 DCM could erode some types of tubing (e.g. polystyrene), accordingly, the recommended  
743 tubing is from PTFE (polytetrafluoroethylene) or PP (polypropylene). Displace the reference  
744 tubing every 2 days (Supplementary Video 1).

745 ■ **PAUSE POINT** The cleared human organs in BABB solution could be stored at room  
746 temperature and covered with aluminium foil for months to years before imaging.

747

#### 748 **Imaging with light-sheet fluorescent microscopy ● Timing 1-8 d**

749 16. Here we use the prototype light-sheet microscope from Miltenyi Biotec to image the  
750 human pancreas (Fig. 3). The commercialized UltraMicroscope Blaze can also be  
751 applied for high resolution imaging of large human organs, they are controlled by the  
752 same software named "Imspector".

- 753 i. Check the sample in BABB solution if there are bubbles inside of organs. If  
754 yes, carefully suck out the bubbles using 1 ml syringe. (Supplementary Video  
755 2)
- 756 ii. On pieces of tissue paper, prepare the clean sample holder, glue, tape and  
757 samples, for example, human pancreas.
- 758 iii. Cut three pieces of tape and stick on the top, middle, bottom parts of sample  
759 holder.
- 760 iv. Add the glue on the tapes of sample holder. To stick the sample durable, the  
761 glue is covering full area of the tapes. **!CAUTION** If the glue is not sufficient,  
762 the sample is not stable on the holder and would shift or fall down during the  
763 2-3 days of scanning.
- 764 v. Use tissue paper to absorb BABB solution from one side of sample several  
765 times.
- 766 vi. The glue would contact the dry side of sample. Carefully put the sample on  
767 the sample holder and try to keep the centre of sample aligning with the  
768 holder. One end of sample should be close to one end of the moving range of  
769 holder (e.g. top to top).
- 770 vii. Waiting for 30-60 seconds until the glue is getting solid.
- 771 viii. Put the sample holder back to the light-sheet microscope and fix it.
- 772 ix. Check again the sample in BABB solution of chamber if there are bubbles  
773 inside of organs. If yes, carefully suck out the bubbles using 1 ml syringe.
- 774 **!CAUTION** Gently touch the sample when sucking out bubbles, otherwise, the  
775 glue bonding would be destroyed mechanically and the sample would shift or  
776 fall down.

777 17. Setting imaging parameters in Imspector software. (Supplementary Fig. 3)

- 778 i. Go to "Settings" → "Hardware" → "Ultra3 Settings" → "Objective" to choose  
779 the right objective, for example "LVBT 1x".



- 780 ii. Start the View-settings of software with:
- 781 iii. “Measurement Mode” to be “Multi Color Mosaic Acquisition”;
- 782 “Devices 1” to be “Ultra3 filter”;
- 783 “Devices 2” to be “xyz-Table Z”;
- 784 “Devices 3” to be “xyz-Table X”;
- 785 “Devices 4” to be “xyz-Table Y”;
- 786 “AS” means autosave, to be “abled” in green;
- 787 “Split” to be “abled for Devices 1”;
- 788 “Channel Setup” to click the targeted scanning channels according to the
- 789 labelling, “Excitation 561, Emission 595/40” and “Excitation 785, Emission
- 790 empty” here;
- 791 “Sheet NA” to be “0.035”, means “Thickness” to be “21  $\mu\text{m}$ ”;
- 792 “Sheet Width” to be “100%”;
- 793 “Zoom” to be “1.0x”;
- 794 “Measurement  $\rightarrow$  Liquid” to be “BABB”;
- 795 “Measurement  $\rightarrow$  Mount” to be “None”;
- 796 “Exposure Time” to be “90.000-100.000”;
- 797 “Gain” to be “16-bit low noise”;
- 798 “Step” means the step size in  $\mu\text{m}$  between each two images in Z axis, for
- 799 example, “-8.00” is set for human pancreas;
- 800 **!CAUTION** The smaller the step size, the more number of images will be
- 801 acquired, and the scanning will take longer, but the resolution in XZ and YZ
- 802 direction will increase.
- 803 iv. “LightSheet Selection” to be only “left” or only “right” when checking the signal
- 804 and position of sample.
- 805 v. With one side of laser running, adjust the sample stage in Z direction till the
- 806 laser only illuminates close to top surface of sample as starting position of
- 807 scanning. (Supplementary Video 3).
- 808 **!CAUTION** Avoid collision of moving objective with the sample in finding focus
- 809 step, and the sample should only be illuminated on the surface in the starting
- 810 position step.
- 811 vi. Mount the 1.1x objective and then click the “Focus  $\rightarrow$  down” button in the
- 812 software until the lens get immersed in BABB solution of chamber, adjust the
- 813 movement of the objective and gets a clear and bright signal place as focus.
- 814 Then lower the sample holder until the sample is just lower than the light sheet
- 815 illumination region, click “Current Position  $\rightarrow$  “Set as Zero” and “Scan Range
- 816  $\rightarrow$  Start” to be “0.000”.
- 817 **? TROUBLESHOOTING**
- 818 vii. Next lifting up the sample holder, the signal gets blurry when imaging plane
- 819 gets deeper in the sample. Then Click “Scan Range  $\rightarrow$  End”. Since the light
- 820 sheet microscopy 1.1x objective working distance is around 17mm in z
- 821 direction, the maximum imaging depth would be -14 mm.
- 822 viii. Adjust “Mosaic  $\rightarrow$  Set Parameters” to find the proper “X Axis, Y Axis” and
- 823 “Overlap” to cover the scanning volume of samples from edges. In general, for
- 824 1.1x objective, “3x8” with 30% overlapping or “4x7” with 33% overlapping
- 825 would cover the human pancreas or human kidney. For 12x objective, “10x10”
- 826 with 30-40% overlapping is possible. **!CAUTION** Following image stitching will
- 827 be less accurate if overlapping value is set too small. When setting the



- 828 scanning volume, do NOT touch the travelling limitations of stage in X or Y  
829 direction, do NOT touch the objective in Z direction. Otherwise, the software  
830 would report error and fail.
- 831 ix. Choose “Autosave Settings” to fill in the “path” and “name” for saving, such as  
832 “humanpancreas\_1x\_4x7\_33o\_90ex\_8um\_56130\_78540\_forwardup”;
  - 833 x. Stop the live “View”, and Click the “Lightsheet Selection” to be “both”;
  - 834 xi. Start the scanning and keep the room in dark for around 2-3 days.
  - 835 xii. When the scanning finished, take the sample holder out and cut the tapes to  
836 remove the sample from holder. Put the sample in BABB solution and pill off  
837 the glue and tape at the same time. Wash the sample holder with 100% EtOH  
838 and clean with tissue paper.
  - 839 xiii. Repeat i-xix, change the position of the sample or flip the sample in step vi to  
840 make sure the scanning covers both ends and both sides of sample. For  
841 example, human pancreas took four times of scanning to finishing the whole  
842 organ imaging covering forward-up, forward-down, backward-up, backward-  
843 down.

#### 844 **Data stitching, renaming and compression ● Timing 1-2 d**

- 846 18. When the first round of scanning is finished, TIFF files are generated from light-sheet  
847 microscope in the autosave folder. Create new folders inside this autosave folder with  
848 names of C00, C01... for the stitched images, corresponding to the image channels.
- 849 i. Open Fiji, click “Plugins” → “Stitching” → “deprecated” → “Stitch Sequence of  
850 Grids of Images”.
  - 851 ii. Correct the “Stitch Image Grid Sequence” with the right information from the  
852 scans in terms of “grid size x”, “grid size y”, “grid size z”, “overlap”, “Input  
853 directory”, “file names”, “Output directory”, “start x”, “start y”, “start z”, “start i”,  
854 and the other settings are accepted as default.  
855 “grid size x” to be the number of “X Axis” in light-sheet microscope scanning.  
856 “grid size y” to be the number of “Y Axis” in light-sheet microscope scanning.  
857 “grid size z” to be “1”.  
858 “overlap” to be the number of “Overlap” in light-sheet microscope scanning.  
859 “Input directory” to be the path of the autosave folder.  
860 “file names”: copy the name of first .tif image from the autosave folder to here  
861 and replace Ultra3[00 x 00] to be Ultra3[{yy} x {xx}], Z0000 to be Z{zzzz}.  
862 “Output directory” to be the path of “C00” folder inside the autosave folder.  
863 “Start x” to be “0”.  
864 “Start y” to be “0”.  
865 “Start z” to be “any number small than the total number of images”, in general,  
866 we choose a number in the middle.  
867 “Start i” to be “1”.
  - 868 iii. Click “OK” and wait for the running of stitching.
  - 869 iv. Open the new stitched image (Number is the setting in “Start z”.) in folder  
870 “C00” with Fiji to check if the image quality is OK. **! OPTIONAL** Other  
871 alternative algorithms are recommended, for example, TeraStitcher  
872 (<https://abria.github.io/TeraStitcher/>).  
873 **? TROUBLESHOOTING**

- 874 v. With the finishing of first stitching, a file called  
875 "TileConfiguration.text.registered" would be generated in the "Input folder",  
876 which contains the stitching parameters and coordinates of tiles information.
- 877 vi. Rename this file to delete the ".registered" part and to generate a .txt file,  
878 "TileConfiguration\_(zzz)(2)".
- 879 vii. Copy this file into folder "C00" and open it, the "C00\_xyz-Table Zxxxx" shows  
880 the number as set in the step xiv "Start z". Revise the "Zxxxx" to "Z0000" in all  
881 tiles.
- 882 viii. Copy this new "TileConfiguration\_(zzz)(2)" file to other channel folders and  
883 revise the "C00\_xyz-Table" in all tiles to responding channel number, for  
884 example, "C00" to "C01" in folder "C01"; "C00" to "C02" in folder "C02". Each  
885 channel requires its own "TileConfiguration\_(zzz)(2)" file with corresponding  
886 channel number and saved in the respective folder.
- 887 ix. Open the file "Stitching.py" with Fiji, which would run the  
888 "TileConfiguration\_(zzz)(2)" file to finish all stitching.
- 889 x. Click "run", and load the "TileConfiguration\_(zzz)(2)" file, fill in the total  
890 numbers of scanning images.
- 891 xi. Repeat vii-viii for each "TileConfiguration\_(zzz)(2)" file in each channel folder.
- 892 xii. All stitched images would be separately saved in corresponding channel  
893 folders, "C00", "C01"...
- 894 xiii. Since the stitched tiff images are named with sequential numbers in each  
895 channel folder, we would use "Total Commander" software to rename each of  
896 the images. Run the software, on the left panel, open the file of stitched folder  
897 "C00", choose all "Manual\_StitchedZxxxx" images, "Files" → "Multi-Rename  
898 Tool" .  
899 "file name" to be "C00\_Z". Then click "[C] Counter".  
900 "Define counter [C]" to be "Start at 0", "Step by 1" and "Digits 4".  
901 Click "Start!" button and the software would rename all  
902 "Manual\_StitchedZxxxx" images in folder C00 to be "C00\_Zxxxx".
- 903 xiv. Repeat xiii for other channel folders, for example, "C01" to rename the  
904 "Manual\_StitchedZxxxx" images in folder C01 to be "C01\_Zxxxx".
- 905 xv. Transfer all stitched images from different channel folders into one folder, for  
906 example, "C00".
- 907 xvi. Run "LZW compression" using software "ImageMagick" to compress all  
908 stitched images in folder "C00".
- 909 xvii. Repeat i-xvi for all different volumetric light-sheet microscopy scans. For  
910 example, human pancreas would generate four stitched image folders from  
911 four times of scanning.

### 913 Arivis fusion ● Timing 1-6 d

- 914 19. Use "Arivis Vision 4D" to merge multiple 3D volumes.
- 915 i. Open "Arivis SIS Converter" → "Add Files" to load all of the stitched images  
916 from different channels in C00 folder. If "Assume same structure for all files?"  
917 shows up, click "Yes".
- 918 ii. "Import Files" → "Custom import" → "Browse" to choose the output folder, →  
919 "File Name" to define the name of Arivis file, for example, "Human  
920 pancreas\_forward up.sis". ▲CRITICAL All stitched images from different  
921 channels must be in the same folder.

- 922           iii.   “more options” → “Target Pixel Type” → “16-Bit integer”.
- 923           iv.   Click “OK” → “Manual import mapper” → “Selection” → “Pattern matching” →
- 924           “OK” to load the right information of images about channels and image planes.
- 925           v.   “Start” to convert all stitched images from different channels into Arivis file.
- 926           **!CAUTION** The .sis Arivis file could be several Terabytes after fusion, for
- 927           example, human pancreas has 2.5 Terabytes. It is important to save the .sis
- 928           files in the local drive with enough capacity. The running of Arivis could fail
- 929           due to poor connection to network drive.
- 930           vi.   Repeat i-iv to convert all volumetric scans of sample, for example, human
- 931           pancreas has four Arivis files, corresponding to forward-up, forward-down,
- 932           backward-up, backward-down.
- 933           vii.   Double click the first .sis file to open the Arivis Vision 4D.
- 934           viii.   “Data” → “Pixel Size” to revise the X, Y, Z number to be the correct size from
- 935           the light-sheet microscopy scanning settings. For example, 1.1x objective has
- 936           the pixel size of  $6.5/1.1=5.909 \mu\text{m}$  in X and Y; 4x objective has the pixel size
- 937           of  $6.5/4=1.625 \mu\text{m}$  in X and Y; 12x objective has the pixel size of  $6.5/12=0.542$
- 938            $\mu\text{m}$  in X and Y. The Z pixel size is the “Step size” parameter. Click “Change
- 939           Pixel Size”. “Save” the file.
- 940           ix.   Click the “i” button on the left corner to check the image information with
- 941           “Image Set” and “Plane”, which should be “16 bit” and “number of total
- 942           images”.
- 943           x.   To load the second volumetric scans, “File” → “Import” to choose the second
- 944           .sis file, → “Import Files” → “more options” → “Import as New Image set” →
- 945           “Target Pixel Type” to be “16 Bit integer”. **▲CRITICAL** The pixel type should
- 946           be matched for all loaded volumetric files.
- 947           xi.   When the second .sis file loading finishes, revise the pixel size following step
- 948           vii again and save the file.
- 949           xii.   Click the button on the right corner of presenting as “Vertical Split”. “Navigator”
- 950           → “Images Set” to show the two volumetric scans separately (one is default
- 951           file), scroll the 2D images to zoom in and out for better view of data, adjust the
- 952           color bar of each channel for the brightness and contrast.
- 953           xiii.   If the two volumetric scans are from different side of sample scanning, “Data”
- 954           → “Transformation Gallery” → “Available Transformations” → “Flipping” →
- 955           “Flipping Properties” → “Flip X-Axis” or “Flip Y-Axis” or “Flip Z-Axis” to match
- 956           the X, Y, Z orientations of both volumes. Click “OK” to run it. “Save” the file
- 957           again after finishing.
- 958           xiv.   A new image set would show up in the “Image Set”, open the “default” and
- 959           “flipped” files with same orientations.
- 960           xv.   In the overlapping volume, identify at least three landmarks in both of the two
- 961           image sets by zooming in or out and adjusting the planes. **▲CRITICAL** The
- 962           landmarks could be the same cell, the same hole, the same vessel structure
- 963           or the same junctions. The landmarks should cover the overlapping volume as
- 964           much as possible. For example, the first landmark is labeled from the top-right
- 965           area in the beginning of Z plane, the second landmark is labeled from the
- 966           middle-left area in the middle of Z plane and the third landmark is labeled from
- 967           the bottom-right area in the last of Z plane. So the three landmarks could form
- 968           triangles in any of the XY, YZ and XZ planes. If possible, identify more

- 969 landmarks in each of these areas in case wrong labels happen due to the  
 970 different scanning angle from the light-sheet.
- 971 xvi. Click the icon “Place New Object” → “Marker” to label the same landmarks in  
 972 both image sets and colorful squares would show up. Click “Show Objects  
 973 Table” to view the information of markers.
- 974 xvii. Click “Data” → “Volume Fusion” → “Image Sets” to choose the right “Base  
 975 Image Set” and “Moving Image Set”, “Save as” choose “New File”, “Image Set  
 976 Name” to define the name for new fusion. “Transformation” → “landmark  
 977 Registration” → “Base Image Set” → “ Add All Objects as Landmarks” by right  
 978 clicking the set icon. Do the same for “Moving Image Set”. Right click marker  
 979 to delete the unwanted ones. In the end, three same landmarks are enough.  
 980 “Scale” to be “10%”. Click “Run” to finish the trials of fast volume fusion for  
 981 preview. ▲ **CRITICAL** The sequence of landmarks should be the same in both  
 982 image sets. The highlighted locations of landmarks would display in the right  
 983 window.
- 984 xviii. If the new fusion is not good, for example, with mismatching, gap or ghosting,  
 985 try different combinations of three different landmarks to get the best fusion  
 986 quality in both 2D view and 3D view.
- 987 xix. If fusion is good enough, change the “Scale” to be “100%” and run the final  
 988 fusion to generate the new .sis file with both volume sets.
- 989 xx. Click “Show Objects Table” to view the information of markers, → “Im/Export”  
 990 → “Excel Export” → “Save As” to choose the folder, → “Export” to keep the  
 991 record of landmarks for both image sets.
- 992 xxi. Repeat step vi-xix to fuse each of other parts of volumetric scan into the new  
 993 fused file. For example, repeat three times of the process to generate the final  
 994 3D fusion .sis file for human pancreas.
- 995 xxii. “File” → “Export” → “TIFF Exporter” and define the file name in a new folder to  
 996 generate a series of .tif images. All final fused images from all channels would  
 997 be saved in the folder.
- 998 xxiii. Run “Total Commander” software to rename each of the images. Run the  
 999 software, on the left panel, open the files in the saved folder, “Mark” → “Select  
 1000 Group” → input “C00” → “OK” to choose all files containing the “C00”.
- 1001 xxiv. “Files” → “Multi-Rename Tool” → “file name” to be “C00\_Z”, Click “[C]  
 1002 Counter”, “Define counter [C]” to be “Start at 0”, “Step by 1” and “Digits 4”.  
 1003 Click “Start!” button and the software would rename all images with “C00” in  
 1004 the saved folder to be “C00\_Zxxxx”.
- 1005 xxv. Repeat xxii-xxiii to rename the fused images for other channels.
- 1006 xxvi. Run “LZW TIFF 16bit” to compress all fused images in the saved folder.

### ? TROUBLESHOOTING

#### Imaris 3D visualization ● Timing ~0.5-2 d

- 1009 20. Here we only include the basic and simple steps for Imaris 3D visualization. For more  
 1010 functional analysis, please check the Imaris website for user guide.
- 1011 i. Open “Imaris File Converter” → “Add Files” to load all of the fused images in  
 1012 the saved folder. Define the save path in “Output”.
- 1013 ii. Click on the loaded files → “Settings” → Select “File names with delimiter”,  
 1014 confirm the format as C“C”\_Z“Z”.tif. Then click “Start All”.
- 1015 iii. Following the save path, an “Imaris Image File” is generated.

- 1016 iv. Double click to open the Imaris file, “Edit” → “Image Properties” →  
1017 “Geomertry” → “Voxel Size”. X=6.5/objective, Y=6.5/objective, Z= “z” step size  
1018 in the imaging setting. For example, if choosing the 1x Objective with a z step  
1019 of 8  $\mu\text{m}$ , then X=6.5  $\mu\text{m}$ , Y=6.5  $\mu\text{m}$ , Z=8  $\mu\text{m}$ . if choosing the 12x Objective  
1020 with a z step of 6  $\mu\text{m}$ , then X=0.542  $\mu\text{m}$ , Y=0.542  $\mu\text{m}$ , Z= 6  $\mu\text{m}$ .
- 1021 v. “Edit” → “Show Display Adjustment” to change the channel colors and adjust  
1022 the contrast.
- 1023 vi. “Imaging Processing” → “Camera Function” → “Set The Angle Of The  
1024 Camera” to set needed 3D views.
- 1025 vii. “Snapshot” → “Preferences” → “Snapshot” to set the Size, DPI (at least 300),  
1026 Save as Type (TIFF images), Image Output Directory.
- 1027

## 1028 **Timing**

1029 See Table 4.

1030

## 1031 **Troubleshooting**

1032 See Table 5.

1033

## 1034 **Anticipated Results**

1035 We described SHANEL in the presented protocol as a scalable tissue labelling and clearing  
1036 method for a variety of human organs (Supplementary Video 4), including pancreas (Figs. 3-  
1037 5), kidney, and additional vessel labelling of spleen, heart and lung compared to our original  
1038 publication (Fig. 5), we also extend the original method to be compatible with human hard  
1039 tissue with bone (Fig. 7). SHANEL allows imaging of intact human organs at cellular  
1040 resolution, which paves the way for human organ mapping, and potentially extends our  
1041 knowledge in human organ anatomy. The technique can be used to study vascular  
1042 morphology and pathology, as the fine details of capillary can be visualized throughout whole  
1043 organ (Fig. 5).

1044

1045 We previously used SHANEL to label and quantify the pancreas islets in *INS*-EGFP  
1046 transgenic pig<sup>20</sup>, demonstrating the scalability of this method to study large scale biological  
1047 samples. SHANEL is also applicable for antibody staining in human tissue or biopsies (Fig.  
1048 6), increasing its adaptability in biomedical research.

1049

1050 After using the recently developed LSFM to image the transparent human organs or tissues  
1051 and to therefore acquire spatial information of vessels and fluorescent protein signal (Fig. 3,  
1052 Supplementary Fig. 3), the whole data set can be efficiently stitched with an easily operated  
1053 software (Supplementary Fig. 4). Here, we show an example of how raw images were  
1054 processed and visualization for the entire 3D fields and cellular states information was rapidly  
1055 achieved in a simple-to-use software (Supplementary Fig. 5-6). Note that, due to the size of  
1056 human organs, terabytes of the image data will be generated. Consequently, it would be  
1057 suggested to combine our methodology with deep learning approaches to achieve accuracy  
1058 and speed in quantification and further analysis. We summarize a workflow (Supplementary  
1059 Fig. 7) that will be useful for researchers in order to select critical steps and apply this  
1060 protocol.

1061

## 1062 **Acknowledgement**

1063 We thank Alireza Ghasemi Mag for developing the python script “Stitching.py” to stitch  
1064 sequences of images. We thank Izabela Horvath for revising the manuscript. We thank  
1065 Miltenyi Biotec for providing the PE-conjugated antibodies. Schematic of SHANEL pipeline is  
1066 created with BioRender.com. This work was supported by the Vascular Dementia Research  
1067 Foundation, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under  
1068 Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems  
1069 Neurology (EXC 2145 SyNergy, ID 390857198), H.M. and Z.R. would like to thank the China  
1070 Scholarship Council (CSC) for the financial support (No. 201806780034 and No.  
1071 201806310110).

1072

## 1073 **Author Contributions**

1074 A.E. conceived and led the project. S.Z. developed the original SHANEL protocol. H.M., Z.R.  
1075 and S.Z. performed the experiments and wrote the manuscript. R.C. performed the antibody  
1076 screening. H.S. and I.B. dissected and provided the human organs. All authors commented  
1077 on the manuscript text.

1078

## 1079 **Data availability**

1080 The raw data that support the findings of this study are available from the corresponding  
1081 author upon reasonable request.

1082

## 1083 **Competing interests**

1084 A.E. and S.Z. filed a patent on SHANEL technologies described in this study.

1085

## 1086 **Additional information**

1087 Supplementary information is available at <http://discotechnologies.org/SHANEL/>.

1088

## 1089 **References**

1090

1091

- 1092 1 Snyder, M. P. *et al.* The human body at cellular resolution: the NIH Human Biomolecular Atlas  
1093 Program. *Nature* **574**, 187-192, doi:10.1038/s41586-019-1629-x (2019).
- 1094 2 Rood, J. E. *et al.* Toward a Common Coordinate Framework for the Human Body. *Cell* **179**,  
1095 1455-1467, doi:10.1016/j.cell.2019.11.019 (2019).
- 1096 3 Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A. The Human Cell  
1097 Atlas: from vision to reality. *Nature* **550**, 451-453, doi:10.1038/550451a (2017).
- 1098 4 Srivastava, S., Ghosh, S., Kagan, J. & Mazurchuk, R. The PreCancer Atlas (PCA). *Trends Cancer*  
1099 **4**, 513-514, doi:10.1016/j.trecan.2018.06.003 (2018).
- 1100 5 Ardini-Poleske, M. E. *et al.* LungMAP: The Molecular Atlas of Lung Development Program. *Am*  
1101 *J Physiol Lung Cell Mol Physiol* **313**, L733-L740, doi:10.1152/ajplung.00139.2017 (2017).
- 1102 6 Amunts, K. *et al.* BigBrain: an ultrahigh-resolution 3D human brain model. *Science* **340**, 1472-  
1103 1475, doi:10.1126/science.1235381 (2013).
- 1104 7 Deverman, B. E. *et al.* Cre-dependent selection yields AAV variants for widespread gene  
1105 transfer to the adult brain. *Nat Biotechnol* **34**, 204-209, doi:10.1038/nbt.3440 (2016).
- 1106 8 Erturk, A. *et al.* Three-dimensional imaging of solvent-cleared organs using 3DISCO. *Nat*  
1107 *Protoc* **7**, 1983-1995, doi:10.1038/nprot.2012.119 (2012).

1108 9 Cai, R. *et al.* Panoptic imaging of transparent mice reveals whole-body neuronal projections  
1109 and skull-meninges connections. *Nat Neurosci* **22**, 317-327, doi:10.1038/s41593-018-0301-3  
1110 (2019).

1111 10 Pan, C. *et al.* Shrinkage-mediated imaging of entire organs and organisms using uDISCO. *Nat*  
1112 *Methods* **13**, 859-867, doi:10.1038/nmeth.3964 (2016).

1113 11 Park, Y. G. *et al.* Protection of tissue physicochemical properties using polyfunctional  
1114 crosslinkers. *Nat Biotechnol*, doi:10.1038/nbt.4281 (2018).

1115 12 Renier, N. *et al.* Mapping of Brain Activity by Automated Volume Analysis of Immediate Early  
1116 Genes. *Cell* **165**, 1789-1802, doi:10.1016/j.cell.2016.05.007 (2016).

1117 13 Belle, M. *et al.* Tridimensional Visualization and Analysis of Early Human Development. *Cell*  
1118 **169**, 161-173 e112, doi:10.1016/j.cell.2017.03.008 (2017).

1119 14 Pan, C. *et al.* Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in  
1120 the Entire Body. *Cell* **179**, 1661-1676 e1619, doi:10.1016/j.cell.2019.11.013 (2019).

1121 15 Kubota, S. I. *et al.* Whole-Body Profiling of Cancer Metastasis with Single-Cell Resolution. *Cell*  
1122 *Rep* **20**, 236-250, doi:10.1016/j.celrep.2017.06.010 (2017).

1123 16 Lai, H. M. *et al.* Next generation histology methods for three-dimensional imaging of fresh  
1124 and archival human brain tissues. *Nat Commun* **9**, 1066, doi:10.1038/s41467-018-03359-w  
1125 (2018).

1126 17 Morawski, M. *et al.* Developing 3D microscopy with CLARITY on human brain tissue: Towards  
1127 a tool for informing and validating MRI-based histology. *Neuroimage* **182**, 417-428,  
1128 doi:10.1016/j.neuroimage.2017.11.060 (2018).

1129 18 Hildebrand, S., Schueth, A., Herrler, A., Galuske, R. & Roebroek, A. Scalable Labeling for  
1130 Cytoarchitectonic Characterization of Large Optically Cleared Human Neocortex Samples. *Sci*  
1131 *Rep* **9**, 10880, doi:10.1038/s41598-019-47336-9 (2019).

1132 19 Ku, T. *et al.* Elasticizing tissues for reversible shape transformation and accelerated molecular  
1133 labeling. *Nat Methods* **17**, 609-613, doi:10.1038/s41592-020-0823-y (2020).

1134 20 Zhao, S. *et al.* Cellular and Molecular Probing of Intact Human Organs. *Cell* **180**, 796-812  
1135 e719, doi:10.1016/j.cell.2020.01.030 (2020).

1136 21 Murakami, T. C. *et al.* A three-dimensional single-cell-resolution whole-brain atlas using  
1137 CUBIC-X expansion microscopy and tissue clearing. *Nat Neurosci* **21**, 625-637,  
1138 doi:10.1038/s41593-018-0109-1 (2018).

1139 22 Matsumoto, K. *et al.* Advanced CUBIC tissue clearing for whole-organ cell profiling. *Nat*  
1140 *Protoc* **14**, 3506-3537, doi:10.1038/s41596-019-0240-9 (2019).

1141 23 Susaki, E. A. *et al.* Whole-brain imaging with single-cell resolution using chemical cocktails  
1142 and computational analysis. *Cell* **157**, 726-739, doi:10.1016/j.cell.2014.03.042 (2014).

1143 24 Tainaka, K. *et al.* Whole-body imaging with single-cell resolution by tissue decolorization. *Cell*  
1144 **159**, 911-924, doi:10.1016/j.cell.2014.10.034 (2014).

1145 25 Chung, K. *et al.* Structural and molecular interrogation of intact biological systems. *Nature*  
1146 **497**, 332-337, doi:10.1038/nature12107 (2013).

1147 26 Ku, T. *et al.* Multiplexed and scalable super-resolution imaging of three-dimensional protein  
1148 localization in size-adjustable tissues. *Nat Biotechnol* **34**, 973-981, doi:10.1038/nbt.3641  
1149 (2016).

1150 27 Treweek, J. B. *et al.* Whole-body tissue stabilization and selective extractions via tissue-  
1151 hydrogel hybrids for high-resolution intact circuit mapping and phenotyping. *Nat Protoc* **10**,  
1152 1860-1896, doi:10.1038/nprot.2015.122 (2015).

1153 28 Tainaka, K. *et al.* Chemical Landscape for Tissue Clearing Based on Hydrophilic Reagents. *Cell*  
1154 *Rep* **24**, 2196-2210 e2199, doi:10.1016/j.celrep.2018.07.056 (2018).

1155 29 Lai, H. M., Ng, W. L., Gentleman, S. M. & Wu, W. Chemical Probes for Visualizing Intact  
1156 Animal and Human Brain Tissue. *Cell Chem Biol* **24**, 659-672,  
1157 doi:10.1016/j.chembiol.2017.05.015 (2017).



1158 30 Cequier-Sánchez, E., Rodríguez, C., Ravelo, A. G. & Zárata, R. Dichloromethane as a solvent  
1159 for lipid extraction and assessment of lipid classes and fatty acids from samples of different  
1160 natures. *J Agric Food Chem* **56**, 4297-4303, doi:10.1021/jf073471e (2008).

1161 31 Schmidt, M. M. D., R. C. P. ; Mello, R. O. ; Kubota, E. H. ; Mazutti, M. A. ; Kempka, A. P. ;  
1162 Demiate, I. M. Collagen extraction process. *International Food Research Journal* **23**, 913-922  
1163 (2016).

1164 32 Yanagishita, M., Podyma-Inoue, K. A. & Yokoyama, M. Extraction and separation of  
1165 proteoglycans. *Glycoconj J* **26**, 953-959, doi:10.1007/s10719-008-9138-4 (2009).

1166 33 Todorov, M. I. *et al.* Machine learning analysis of whole mouse brain vasculature. *Nat*  
1167 *Methods* **17**, 442-449, doi:10.1038/s41592-020-0792-1 (2020).

1168 34 Ugryumova, N., Matcher, S. J. & Attenburrow, D. P. Measurement of bone mineral density  
1169 via light scattering. *Phys Med Biol* **49**, 469-483, doi:10.1088/0031-9155/49/3/009 (2004).

1170 35 Greenbaum, A. *et al.* Bone CLARITY: Clearing, imaging, and computational analysis of  
1171 osteoprogenitors within intact bone marrow. *Sci Transl Med* **9**,  
1172 doi:10.1126/scitranslmed.aah6518 (2017).

1173 36 Grüneboom, A. *et al.* A network of trans-cortical capillaries as mainstay for blood circulation  
1174 in long bones. *Nature Metabolism* **1**, 236-250, doi:10.1038/s42255-018-0016-5 (2019).

1175 37 Gonzalez-Chavez, S. A., Pacheco-Tena, C., Macias-Vazquez, C. E. & Luevano-Flores, E.  
1176 Assessment of different decalcifying protocols on Osteopontin and Osteocalcin  
1177 immunostaining in whole bone specimens of arthritis rat model by confocal  
1178 immunofluorescence. *Int J Clin Exp Pathol* **6**, 1972-1983 (2013).

1179 38 Savi, F. M., Brierly, G. I., Baldwin, J., Theodoropoulos, C. & Woodruff, M. A. Comparison of  
1180 Different Decalcification Methods Using Rat Mandibles as a Model. *J Histochem Cytochem*  
1181 **65**, 705-722, doi:10.1369/0022155417733708 (2017).

1182 39 Liu, A. K. *et al.* Bringing CLARITY to the human brain: visualization of Lewy pathology in three  
1183 dimensions. *Neuropathol Appl Neurobiol* **42**, 573-587, doi:10.1111/nan.12293 (2016).

1184 40 Murray, E. *et al.* Simple, Scalable Proteomic Imaging for High-Dimensional Profiling of Intact  
1185 Systems. *Cell* **163**, 1500-1514, doi:10.1016/j.cell.2015.11.025 (2015).

1186 41 Perbellini, F. *et al.* Free-of-Acrylamide SDS-based Tissue Clearing (FASTClear) for three  
1187 dimensional visualization of myocardial tissue. *Sci Rep* **7**, 5188, doi:10.1038/s41598-017-  
1188 05406-w (2017).

1189 42 Nojima, S. *et al.* CUBIC pathology: three-dimensional imaging for pathological diagnosis. *Sci*  
1190 *Rep* **7**, 9269, doi:10.1038/s41598-017-09117-0 (2017).

1191 43 Jensen, K. H. & Berg, R. W. CLARITY-compatible lipophilic dyes for electrode marking and  
1192 neuronal tracing. *Sci Rep* **6**, 32674, doi:10.1038/srep32674 (2016).

1193 44 Mann, D. M., Yates, P. O. & Stamp, J. E. The relationship between lipofuscin pigment and  
1194 ageing in the human nervous system. *J Neurol Sci* **37**, 83-93, doi:10.1016/0022-  
1195 510x(78)90229-0 (1978).

1196 45 Schnell, S. A., Staines, W. A. & Wessendorf, M. W. Reduction of lipofuscin-like  
1197 autofluorescence in fluorescently labeled tissue. *J Histochem Cytochem* **47**, 719-730,  
1198 doi:10.1177/002215549904700601 (1999).

1199 46 Neumann, M. & Gabel, D. Simple method for reduction of autofluorescence in fluorescence  
1200 microscopy. *J Histochem Cytochem* **50**, 437-439, doi:10.1177/002215540205000315 (2002).

1201 47 Yang, J. *et al.* Quenching autofluorescence in tissue immunofluorescence [version 1; peer  
1202 review: 2 approved with reservations, 1 not approved]. *Wellcome Open Research* **2**,  
1203 doi:10.12688/wellcomeopenres.12251.1 (2017).

1204 48 Helsby, M. A. *et al.* CiteAb: a searchable antibody database that ranks antibodies by the  
1205 number of times they have been cited. *BMC Cell Biol* **15**, 6, doi:10.1186/1471-2121-15-6  
1206 (2014).

1207 49 Voigt, F. F. *et al.* The mesoSPIM initiative: open-source light-sheet microscopes for imaging  
1208 cleared tissue. *Nat Methods* **16**, 1105-1108, doi:10.1038/s41592-019-0554-0 (2019).

1209

## 1210 **Figure Legends**

### 1211 **Figure 1. Overview of SHANEL pipeline**

1212 SHANEL is composed of seven parts. After human organs and tissue are collected (Step 1),  
1213 human organs preparation is performed for removing blood and fixation(Step 2). The  
1214 continuous step is divided into active pumping (Step 3a) and passive incubation(Step 3b),  
1215 based on whether the organs are intact or not. Samples are then following permeabilization,  
1216 delipidation, ECM loosening, and chemical probes labelling. According to the antibodies  
1217 compatible with the SHANEL protocol, the organ of interest can be dissected into less than  
1218 1.5cm thick slices for immunolabelling (Step 4). Samples are then dehydrated, delipidated,  
1219 and matched for refractive index, until transparent (Step 5). Imaging of whole human organs  
1220 is performed in an UltraMicroscope Blaze LSFM, and tissue slices are captured with an  
1221 UltraMicroscope II LSFM for high resolution (Step 6). The data is stitched, volumes fused,  
1222 and rendered in 3D visualization (Step 7).

1223

### 1224 **Figure 2. Vessel labelling with dextran solution by active perfusion**

1225 **(a)** Photo of dissected human kidney with inserted tubing (scale bar: 1 cm). **(b)** The tubing  
1226 was changed to be PTFE (chemical-resistant, anti-adhesive, biocompatible) tube and tightly  
1227 fixed by double rope-fastening (red rectangle in **c**). **(d)** The inserted nozzle of PTFE tube was  
1228 cut with a slope angle to plug-in smoothly. **(e)** A set of connecting tubing contained the black  
1229 pump reference tube in the middle, two white tubes at both ends, tube connectors and a  
1230 pipette. The red arrows indicated the flow circulation direction. **(f)** Vessel labelling with  
1231 dextran solution using pump perfusion system (rotation of the wheel in **g** enables solution  
1232 flow into kidney, black pump reference tube was fastened by correct set up of cassette  
1233 shown in **h**). **(i)** Photos of human kidney after dextran labelling. **(j)** The dextran labeled  
1234 human kidney was sealed in a plastic bag.

1235

### 1236 **Figure 3. Organ mounting and imaging with light-sheet microscopy**

1237 **(a)** Photo of human pancreas before clearing (scale bar: 1 cm). **(b)** Photo of transparent  
1238 human pancreas after PI cell nuclei labelling and clearing, showing mesenteric artery (white  
1239 arrow) and lymph nodes (yellow asterisk) (scale bar: 1 cm). **(c)** The mounting of an organ on  
1240 a sample holder required glue and black tape. The red arrows show the moving range ends  
1241 of holder in Y direction. **(d)** The sample holder was gummed with four sections of tape and  
1242 dropped with glue. **(e)** One example of sample position with one end alignment to cover one  
1243 sample edge. **(f)** Another example of sample position with another end alignment to cover  
1244 the other sample edge. **(g)** The mounted human pancreas was illuminated by light sheet.

1245

### 1246 **Figure 4. 3D reconstruction of human pancreas**

1247 **(a)** 3D reconstruction of human pancreas imaged by light sheet fluorescence microscopy  
1248 focusing on the PI labeled cell nuclei (Green) and autofluorescence of 785 nm wavelength  
1249 (magenta) (scale bar: 1 cm). **(b)** Zoomed 3D reconstruction in figure A showed the vessels  
1250 and lymph nodes (red rectangular) (scale bars: 1 mm and 200um respectively). **(c)** 3D  
1251 reconstruction of one example of endocrine portion by high magnification of 12X objective  
1252 (scale bar: 200 um). **(d)** Diverse islets surrounded by acinar cells could be easily identified in  
1253 3D images of endocrine portion showing standard round or oval shape and irregular shapes  
1254 as well as variable sizes (red asterisk). Also, intralobular ducts could be located near the  
1255 islets (yellow arrow). (scale bars: 50 um, 50 um and 30um, respectively).

1256

1257 **Figure 5. SHANEL of human organs with perfusion of dextran vessel labelling dye**  
1258 (a) Human heart after SHANEL protocol (i), 3D reconstruction (ii) shows blood vessels of  
1259 coronary artery (red) and myocardium which can be imaged in autofluorescence at 488 nm  
1260 (AF, green) (scale bars: 1 cm and 2mm, respectively). (b) Human kidney after SHANEL (i),  
1261 structure of glomeruli can be seen in dextran labelled. TO-PRO3 labelled cell nucleus (scale  
1262 bars: 1 cm and 2mm, respectively). (c) One lobe of human lung was cleared and stained with  
1263 dextran, bronchus can be seen in AF (scale bars: 1 cm and 2mm, respectively). (d) Image of  
1264 human pancreas and vasculature after SHANEL (scale bars: 1 cm and 2mm, respectively).  
1265 (e) Human spleen after SHANEL, fine structure of splenic artery was visualized in Imaris  
1266 (scale bars: 1 cm and 2mm, respectively).

1267  
1268 **Figure 6. SHANEL of human tissues by passive incubation**  
1269 (a) Skull labelled with lectin (yellow) and PI (blue) (i). XY section (ii) and magnified image (iii)  
1270 (scale bars: 1mm, 1mm and 100um, respectively). (b) brain slice labelled with Neurotrace  
1271 Nissl stain. (scale bars: 2mm and 300um, respectively). (c) brain tissue labelled with Iba1  
1272 antibody (i). YZ (ii) and XZ (iii) section, magnified image in XY section (iv) (scale bars: 1000  
1273 um, 700 um, 500 um and 40 um, respectively). (d) human lung tissue labelled with  $\alpha$ -SMA  
1274 antibody (i). YZ (ii) and XZ (iii) section, magnified image in XY section (iv) (scale bars: 700  
1275 um, 500 um, 500 um and 150 um, respectively).

1276  
1277 **Figure 7. Passive incubation, clearing and 3D reconstruction of human pulvinar and**  
1278 **skull**  
1279 (a) Photo of transparent human pulvinar after PI cell nuclei labelling and clearing by passive  
1280 incubation (scale bar: 1 cm). (b) 3D reconstruction of human pulvinar imaged by light-sheet  
1281 fluorescence microscopy focusing on autofluorescence (AF) of 488 nm wavelength (grey)  
1282 and PI labeled cell nuclei (Green) (scale bar: 1 cm). (c) section view of pulvinar showing the  
1283 connection between bone tissue and the pulvinar fibrofatty tissue (scale bar: 150 um). (d)  
1284 Human skull bone after PI cell nuclei labelling and clearing (scale bar: 1 cm). (e) The human  
1285 skull imaged by light-sheet and confocal microscopy (Scale bar 500 um and 200 um,  
1286 respectively).

1287  
1288 **Supplementary Figure 1. Human brain clearing by perfusion system**  
1289 (a) The dissection of human brain with CL and CR (left and right carotids, respectively), VL  
1290 and VR (left and right vertebral arteries, respectively). (b) The human brain after dissection  
1291 and fixation. (c) The set up of human brain clearing by perfusion system under fume hood.  
1292 The human brain was put in a glass container and connected with input and output tubing  
1293 controlled by peristaltic pump. There were four channels to control the four connecting  
1294 tubings as indicated in C i. Two output tubings were connected with the carotids arteries as  
1295 shown in C ii and two output tubings were connected with the vertebral arteries as shown in  
1296 C iii. The input tubings were protected with gauze to avoid solid impurities entering and  
1297 blocking the tubings (see C iv). C v showed the decolorization effects of CHAPS/NMDEA  
1298 according to the blooming of dark green color from the organ. (d) The glass container was  
1299 sealed with several layers of plastic wrap to prevent the volatility of running solutions,  
1300 especially for EtOH, DCM, MeOH. (e) Photo of human brain after SHANEL pre-treatment  
1301 before clearing. Remaining blood in the vessels (b) was decolorized.

1302  
1303 **Supplementary Figure 2. Passively stained conjugated antibody in centimeter-size**  
1304 **human kidney and lung tissue**

1305 Collagen IV, catalase and cytokeratin 19 antibody staining (Green) in human kidney **(a)** and  
1306 lung **(b)**. Top panel shows immunofluorescent staining images in confocal microscopy to  
1307 verify antibody compatibility with SHANEL. Bottom panel shows 3D reconstruction of tissue  
1308 with antibody labelling in Imaris. (scale bars: 20 um and 500 um, respectively)

1309

### 1310 **Supplementary Figure 3. Settings in imaging software**

1311 **(a)** The user interface of Lavisision Inspector software. (i) refer to the setting of objective lens  
1312 and magnification. **(ii)** The names of the devices should be listed in the correct order. **(iii)**  
1313 One example for settings of the tiling scan with 4x7 tiles and 33% overlap.

1314

### 1315 **Supplementary Figure 4. Key steps for data stitching, renaming and compression**

1316 **(a)** One example for correcting information of 'Stitching Image Grid Sequence', and a1  
1317 highlighted the replacement of red letters in step x about 'file names'. **(b)** The key information  
1318 of 'TileConfiguration' txt file, b1 highlighted the responding channel number should be  
1319 corrected and saved in respective separated folder and b2 highlighted the starting Z number  
1320 should be '0000' for all 'TileConfiguration' files. **(c)** The information of 'Stitching.py'. **(d)** One  
1321 example for settings of 'Multi-Rename Tool'. **(e)** One example of compressing tiff files with  
1322 'LZW TIFF'.

1323

### 1324 **Supplementary Figure 5. Key steps for Arivis fusion of 3D images**

1325 **(a)** One example of flipping one volumetric data of X or Y or Z direction to match with another  
1326 volumetric data. **(b)** The overview of two volumetric data showing same XYZ directions after  
1327 flipping. **(c-d)** Examples of identical structural markers from two volumetric data sets for  
1328 fusion. **(e)** Loading of three key markers for best fusion. **(f)** 3D fused image of pancreas from  
1329 two volumetric data sets.

1330

### 1331 **Supplementary Figure 6. Key steps for Imaris data loading and visualization**

1332 **(a)** One example of converting stitched image sequence data to the .ims format using Imaris  
1333 File Converter. **(b)** The settings for file names with delimiter should be changed into "C \_  
1334 Z.tif". **(c)** 3D image properties including XYZ voxel size and channel color can be set in  
1335 Imaris for analysis.

1336

### 1337 **Supplementary Figure 7. Overview of SHANEL workflow**

1338 This workflow summarizes the main steps after organ collection: experimental setup (yellow),  
1339 pre-treatments (blue), labelling and clearing (grey) and imaging (red). We provided two ways  
1340 of handling samples: active perfusion with pump, if the vessels could be connected with  
1341 external tube, and passive incubation with shaker. Moreover, depending on the organ  
1342 components, organ size, targeted labelling, and imaging structures, we outlined the  
1343 differences in the whole process.

1344

Table 1| Challenges of human organ labelling, clearing and imaging

1. Uncontrollable variables from human organ resources related to the pre-mortem state and post-mortem delay.  
**Solution:** Selecting reliable human organ and tissue donation organizations.
2. Extremely complicated chemical compositions in terms of lipidome complexity, myelin density, lipofuscin accumulation and non-soluble, non-enzymatic collagen changes.  
**Solution:** An efficient detergent permeabilization is necessary to render the human tissue accessible to reagents traveling end-to-end through it.
3. Residue blood clots due to the delay of post-mortem dissection.  
**Solution:** Setting up active perfusion system to deliver 0.01 M PBS/heparin before 4% PFA fixation can reduce the blood remain in the vessel as much as possible.
4. Strong autofluorescence at visible wavelengths (400-700 nm) from lipofuscin.  
**Solution:** chemical treatment (e.g. CuSO<sub>4</sub>, Sudan Black B, NaBH<sub>4</sub>) or photobleaching has been reported to reduce autofluorescence. We found that CuSO<sub>4</sub> was greatly efficient in reducing the autofluorescence whilst being compatible with labelling.
5. Advanced transgenic or virus tracing techniques for fluorescent labelling not being applicable for human organs.  
**Solution:** Selecting high binding specificities and affinities chemical probes or antibodies for human organs labelling.
6. Increased costs of reagents and dyes due to the size of human organs.  
**Solution:** Using lower price N-methyldiethanolamine (NMDEA) and CHAPS mixture to achieve the permeabilization and decolorization.
7. Volume of large-sized human organs exceeds the limit of volumetric imaging.  
**Solution:** Developing larger chamber size fully automated light-sheet microscopes to cover the range from entire mice to most human organs.
8. Massive imaging data would be generated and need to be stored and analysed.  
**Solution:** Lempel-Ziv-Welch (LZW) TIFF compression and equip with network attached storage.

1345  
1346  
1347  
1348

Table 2| Dyes and antibodies compatible with SHANEL protocol

	Supplier	Cat no.	Dilution
Hoechst	Invitrogen	H3570	1:1000
PI	Invitrogen	P3566	1:1000
TO-PRO-3	Invitrogen	T3605	1:1000
Neuro trace Nissl	Invitrogen	N21483	1:1000
DRAQ5	Thermo	62251	1:1000

	Fisher			
Methoxy-X04	Tocris	4920	100 uM	
Dextran	Sigma	52194	5 mg/ml	
Congo Red	Sigma	C6277	10 uM	
Lycopersicon Esculentum (Tomato) Lectin	Vector	DL1174	1:200	
Lycopersicon Esculentum (Tomato) Lectin	Vector	DL1178	1:200	
Antibodies	Supplier	Cat no.	Dilution	RRID
Tyrosine Hydroxylase	abcam	ab112	1:200	AB_297840
Ionized calcium binding adapter protein 1 (Iba1)	Wako	019-19741	1:500	AB_839504
Neuropeptide Y	abcam	ab30914	1:200	AB_1566510
Myelin basic protein	Atlas	AMAb91064	1:200	AB_2665784
Laminin	Sigma	L9393	1:200	AB_477163
Alpha-smooth muscle actin	Sigma	C6198	1:500	AB_1840528
CD8	abcam	ab237709	1:200	NA
Angiotensin- converting enzyme 2 (ACE2)	Invitrogen	PA5-20039	1:200	AB_11154831
Conjugated antibodies				
Atto647N- conjugated anti- GFP nanobooster	Chromotek	gba647n- 100	1:1000	AB_2629215
Collagen IV	Miltenyi	130-122-866	1:100	AB_2857566
Catalase	Miltenyi	130-123-367	1:100	AB_2857591
Cytokeratin 19	Miltenyi	130-125-272	1:100	AB_2857769
Antibodies tested on mouse tissue	Supplier	Cat no.	Dilution	RRID
Peripheral-Type Benzodiazepine Receptor	abcam	ab109497	1:500	AB_10862345
Cleaved Caspase9	CST	9509	1:500	AB_2073476
Caspase 9	abcam	ab184786	1:500	NA
Gama-H2AX	Invitrogen	14-9865-82	1:500	AB_2573048

1349  
1350

1351

1352 Table 3| Preparation of dextran working solution

	PMPI	DTT	Dextran	PBS
MW(g/mol)	214.2	154.2	500,000	-
Stock concentration	20 mM	20 mM	-	-
Stock solution	DMSO	PBS	-	-
Weight (mg)	8.6 mg	15.4 mg	500 mg	
Volume of solution	2 ml	5 ml	-	93 ml

1353

1354

1355

1356 Table 4 | Timing

Sample type	Human Kidney	Human Pancreas	Human Spleen	Human heart/lung	Human Pulvinar	Human Brain	Human Skull	Tissue slice/block
PBS wash	1d	1d	1d	1d	1d	2d	1d	1d
Vessel labelling	1d	1d	1d	1d	-	-	-	-
EDTA	-	-	-	-	7d-10d	-	14-20d	-
CHAPS/NMDEA	10d-14d	5d-7d	5d-7d	10d-14d	5d-7d	20d	5d	3d
PBS	1d	1d	1d	2d	1d	3d	1d	1d
50% EtOH	1d	1d	1d	2d	1d	5d	1d	1d
70% EtOH	2d	1d	1d	2d	1d	7d	1d	1d
100% EtOH	2d	1d	1d	3d	1d	7d	1d	1d
100% EtOH	2d+2d	1d	1d	3d	1d	7d	1d	1d
DCM/MeOH	3d	2d	2d	3d	2d	7d	2d	2d
100% EtOH	1d	1d	1d	2d	1d	4d	1d	1d
70% EtOH	2d	1d	1d	2d	1d	5d	1d	1d
50% EtOH	2d	1d	1d	2d	1d	5d	1d	1d
DIH <sub>2</sub> O	1d	1d	1d	2d	1d	3d	8h	8h
Acetic Acid	2d	1d	1d	2d	1d	7d	1d	1d
DIH <sub>2</sub> O	8h	8h	8h	2d	8h	3d	8h	8h
Guanidine HCl	1d	1d	1d	2d	1d	7d	1d	1d
PBS	8h	8h	8h	2d	8h	3d	8h	1d
Cell Nuclei Dye	7d	7d	7d	7d	7d	-	2d	-
Antibody Labelling	-	-	-	-	-	-	-	7-14d
PBS	2d	1d	1d	2d	1d	-	1d	1d
50% EtOH	1d	1d	1d	2d	1d	5d	1d	1d
70% EtOH	2d	1d	1d	2d	1d	7d	1d	1d
100% EtOH	2d	1d	1d	2d	1d	7d	1d	1d
100% EtOH	2d	1d	1d	3d	1d	7d	1d	1d
DCM	3d	1d	1d	3d	1d	7d	1d	1d
BABB	3d-	2d-	2d-	5d-	2d-	7d-	2d-	1d-
Total processing time for each organ	~54-60d	~36-38d	~36-38d	~69-73d	~43-48d	~135d	~43-49d	~32-39d

1357

1358

1359



1360 Table 5 | Troubleshooting table

Step	Problem	Possible reason	Solution
3	Undissolved deposits in dextran vessel labelling solution	Not sufficient mixture	Prepare stock solution and mixture step by step
	Difficult to find vessel	Some organs have tube structure similar to vessel. For example, urine tract in kidney and trachea in lung	Confirm the main arteries from anatomy text book, or ask experts for help
	Organ cannot turn red after dextran injection	Blockages in blood vessels	Use higher pressure or a 50ml syringe to inject dextran solution
4, 6, 7, 14	Solution leakage during active pumping	Disconnection or breakage of tubing	Change new tubing to continue pumping
15	Poor organ shrinkage after clearing	Insufficient incubation with ethanol	Increase incubation time with ethanol
17	The samples are not transparent enough and blurry under microscopy	The samples are not dehydrated enough	Make sure the organs dehydrated enough from the sign of no more shrinkage
		The samples are not in sufficient time of BABB	put the sample in BABB until transparent
17	Shade inside the sample	Not sufficient light sheet width	Optimize sufficient light sheet width
		Light absorption in surface by high-cell density region	Try staining with a lower concentration of dye
17	Vessel labelling only in some regions of the organs	The vessel of organ is not intact	Collect the organs carefully and try not to damage it
		Residual blood clot in the sample	Perfuse sample with sufficient PBS and Heparin before organ harvest
17	Signal cannot be detected in the deeper tissue layer	Short wavelength light cannot penetrate to the tissue due to scattering	Use near infrared wavelength or longer wave length chemical probe or secondary antibodies.
17	Staining worked only on the sample surface	Incubation times were too short, or antibody incubation buffer volumes were too small.	To process repeated staining, samples can be gradually rehydrated starting from Step 6 Vii.
			Also increase incubation times and/or antibody incubation buffer

			volume
17	Sample are not visible during the imaging	Out of focus	Move the stage to find bright halos under objective and set up the right contrast on the computer screen.
17	No positive signal, although the antibody works in IF on tissue sections	Incompatibility with SHANEL protocol	Check antibodies list or prototype with sections pre-treated with SHANEL protocol.
17	Weak or non-detectable antibody signals	Insufficient antibody labelling or incapable antibody for SHANEL protocol	Select the antibody form our verified antibody list or optimize the antibody staining conditions.
17	High autofluorescence	Too long PFA fixation time	Reduce PFA fixation time. Fix the sample in PFA less than four weeks. Change to PBS with sodium azide for long-term storage.
18	Stitching failed with the tiling scans	Sample has movement during imaging	Use enough BABB resistant glue to fix the sample or use a custom made holder to fix the sample.
18	Shade inside the sample	Obstruction, such as bubbles	Remove obstruction, such as using syringe to withdraw bubbles.
18	Data are too large to analyze	Unnecessarily high z-resolution	Optimize the Z steps based on the maximum possible z-resolution of the lens.
		Unnecessarily high overlapping percentage of mosaic	Optimize overlapping percentage
19	Failed with the stitching grids of Images	sample move during scanning	Manual stitching or make sure the sample well fixed in the holder

1361

1362

1363

1364 Supplementary table 1| Antibodies not compatible with SHANEL protocol


Antibodies	Supplier	Cat no.
APC	Calbiochem	OP80100UG
GFAP	Sigma	G3893
NeuN	Millipore	MAB377
Calretinin	abcam	ab702
MMP13	abcam	ab39012
myelin basic protein	abcam	ab7349
Parallbumin	abcam	ab11427
CD133/1	Miltenyi Biotec	130-115-292
Podoplanin	Miltenyi Biotec	130-121-373
CD71	Miltenyi Biotec	130-124-358
CD90	Miltenyi Biotec	130-124-176
CD38	Miltenyi Biotec	130-123-347
JNK2 (MAPK9)	Miltenyi Biotec	130-122-868
CD39	Miltenyi Biotec	130-125-078
WT1	Miltenyi Biotec	130-125-782
CD13	Miltenyi Biotec	130-125-787
CD272 (BTLA)	Miltenyi Biotec	130-125-966

1365




# Small-micelle-mediated Human orgAN Efficient clearing and Labelling (SHANEL) pipeline

## ① Organ resources




Collection from human organ and tissue donation organizations

## ② Human organs preparation




PBS/Heparin perfusion and PFA fixation (1-2 d)

## ③a Active pumping




Vessel labelling (1 d)


## ③b Passive incubation



Decalcification for bone tissue (7-20 d)




## ④ Immunolabelling




Secondary antibody  
Primary antibody  
Antigen

● Dissection to <1.5cm thick slice  
● Select Compatible Antibodies (7-15 d)


## ⑤ Tissue clearing



- Dehydrate with ETOH
- Delipidate with DCM
- RI matching with BABB (7-40 d)




## ⑥ Imaging with light-sheet fluorescent microscopy



- Tissue slice with high resolution imaging (UltraMicroscope II)
- Whole human organs imaging (UltraMicroscope Blaze)

## ⑦ Image analysis




- Data stitching, renaming and compression (1-2 d)
- Arivis fusion (1-6 d)
- Imaris 3D visualization (0.5-2 d)

### Figure 1. Overview of SHANEL pipeline

SHANEL is composed of seven parts. After human organs and tissue are collected (Step 1), human organs preparation is performed for removing blood and fixation (Step 2). The continuous step is divided into active pumping (Step 3a) and passive incubation (Step 3b), based on whether the organs are intact or not. Samples are then following permeabilization, delipidation, ECM loosening, and chemical probes labelling. According to the antibodies compatible with the SHANEL protocol, the organ of interest can be dissected into less than 1.5cm thick slices for immunolabelling (Step 4). Samples are then dehydrated, delipidated, and matched for refractive index, until transparent (Step 5). Imaging of whole human organs is performed in an UltraMicroscope Blaze LSFM, and tissue slices are captured with an UltraMicroscope II LSFM for high resolution (Step 6). The data is stitched, volumes fused, and rendered in 3D visualization (Step 7).






**Figure 2. Vessel labelling with dextran solution by active perfusion**

**(a)** Photo of dissected human kidney with inserted tubing (scale bar: 1 cm). **(b)** The tubing was changed to be PTFE (chemical-resistant, anti-adhesive, biocompatible) tube and tightly fixed by double rope-fastening (red rectangle in **c**). **(d)** The inserted nozzle of PTFE tube was cut with a slope angle to plug-in smoothly. **(e)** A set of connecting tubing contained the black pump reference tube in the middle, two white tubes at both ends, tube connectors and a pipette. The red arrows indicated the flow circulation direction. **(f)** Vessel labelling with dextran solution using pump perfusion system (rotation of the wheel in **g** enables solution flow into kidney, black pump reference tube was fastened by correct set up of cassette shown in **h**). **(i)** Photos of human kidney after dextran labelling. **(j)** The dextran labeled human kidney was sealed in a plastic bag.






### Figure 3. Organ mounting and imaging with light-sheet microscopy

(a) Photo of human pancreas before clearing (scale bar: 1 cm). (b) Photo of transparent human pancreas after PI cell nuclei labelling and clearing, showing mesenteric artery (white arrow) and lymph nodes (yellow asterisk) (scale bar: 1 cm). (c) The mounting of an organ on a sample holder required glue and black tape. The red arrows show the moving range ends of holder in Y direction. (d) The sample holder was gummed with four sections of tape and dropped with glue. (e) One example of sample position with one end alignment to cover one sample edge. (f) Another example of sample position with another end alignment to cover the other sample edge. (g) The mounted human pancreas was illuminated by light sheet.






**Figure 4. 3D reconstruction of human pancreas**


(a) 3D reconstruction of human pancreas imaged by light sheet fluorescence microscopy focusing on the PI labeled cell nuclei (Green) and autofluorescence of 785 nm wavelength (magenta) (scale bar: 1 cm). (b) Zoomed 3D reconstruction in figure A showed the vessels and lymph nodes (red rectangular) (scale bars: 1 mm and 200μm respectively). (c) 3D reconstruction of one example of endocrine portion by high magnification of 12X objective (scale bar: 200 μm). (d) Diverse islets surrounded by acinar cells could be easily identified in 3D images of endocrine portion showing standard round or oval shape and irregular shapes as well as variable sizes (red asterisk). Also, intralobular ducts could be located near the islets (yellow arrow). (scale bars: 50 μm, 50 μm and 30μm, respectively).





**Figure 5. SHANEL of human organs with perfusion of dextran vessel labelling dye**  
 (a) Human heart after SHANEL protocol (i), 3D reconstruction (ii) shows blood vessels of coronary artery (red) and myocardium which can be imaged in autofluorescence at 488 nm (AF, green) (scale bars: 1 cm and 2mm, respectively). (b) Human kidney after SHANEL (i), structure of glomeruli can be seen in dextran labelled. TO-PRO3 labelled cell nucleus (scale bars: 1 cm and 2mm, respectively). (c) One lobe of human lung was cleared and stained with dextran, bronchus can be seen in AF (scale bars: 1 cm and 2mm, respectively). (d) Image of human pancreas and vasculature after SHANEL (scale bars: 1 cm and 2mm, respectively). (e) Human spleen after SHANEL, fine structure of splenic artery was visualized in Imaris (scale bars: 1 cm and 2mm, respectively).






**Figure 6. SHANEL of human tissues by passive incubation**

(a) 3D reconstruction of skull labelled with lectin (yellow) and PI (blue) (i). XY section (ii) and magnified image (iii) (scale bars: 1mm, 1mm and 100 $\mu$ m, respectively). (b) brain slice labelled with Neurotrace Nissl stain (scale bars: 2mm and 300 $\mu$ m, respectively). (c) brain tissue labelled with Iba1 antibody (i). YZ (ii) and XZ (iii) section, magnified image in XY section (iv) (scale bars: 1000  $\mu$ m, 700  $\mu$ m, 500  $\mu$ m and 40  $\mu$ m, respectively). (d) human lung tissue labelled with  $\alpha$ -SMA antibody (i). YZ (ii) and XZ (iii) section, magnified image in XY section (iv) (scale bars: 700  $\mu$ m, 500  $\mu$ m, 500  $\mu$ m and 150  $\mu$ m, respectively).






**Figure 7. Passive incubation, clearing and 3D reconstruction of human pulvinar and skull**

**(a)** Photo of transparent human pulvinar after PI cell nuclei labelling and clearing by passive incubation (scale bar: 1 cm). **(b)** 3D reconstruction of human pulvinar imaged by light-sheet fluorescence microscopy focusing on autofluorescence (AF) of 488 nm wavelength (grey) and PI labeled cell nuclei (Green) (scale bar: 1 cm). **(c)** section view of pulvinar showing the connection between bone tissue and the pulvinar fibrofatty tissue (scale bar: 150 um). **(d)** Human skull bone after PI cell nuclei labelling and clearing (scale bar: 1 cm). **(e)** The human skull imaged by light-sheet and confocal microscopy (Scale bar 500 um and 200 um, respectively).






### Supplementary Figure 1. Human brain clearing by perfusion system

(a) The dissection of human brain with CL and CR (left and right carotids, respectively), VL and VR (left and right vertebral arteries, respectively). (b) The human brain after dissection and fixation. (c) The set up of human brain clearing by perfusion system under fume hood. The human brain was put in a glass container and connected with input and output tubing controlled by peristaltic pump. There were four channels to control the four connecting tubings as indicated in C i. Two output tubings were connected with the carotids arteries as shown in C ii and two output tubings were connected with the vertebral arteries as shown in C iii. The input tubings were protected with gauze to avoid solid impurities entering and blocking the tubings (see C iv). C v showed the decolorization effects of CHAPS/NMDEA according to the blooming of dark green color from the organ. (d) The glass container was sealed with several layers of plastic wrap to prevent the volatility of running solutions, especially for EtOH, DCM, MeOH. (e) Photo of human brain after SHANEL pretreatment before clearing. Remaining blood in the vessels (b) was decolorized.






**Supplementary Figure 2. Passively stained conjugated antibody in centimeter-size human kidney and lung tissue**

Collagen IV, catalase and cytokeratin 19 antibody staining (Green) in human kidney (a) and lung (b). Top panel shows immunofluorescent staining images in confocal microscopy to verify antibody compatibility with SHANEL. Bottom panel shows 3D reconstruction of tissue with antibody labelling in Imaris. (scale bars: 20  $\mu\text{m}$  and 500  $\mu\text{m}$ , respectively)










### Supplementary Figure 3. Settings in imaging software


(a) The user interface of Lavisoin Inspector software. (i) refer to the setting of objective lens and magnification. (ii) The names of the devices should be listed in the correct order. (iii) One example for settings of the tiling scan with 4x7 tiles and 33% overlap.





**Supplementary Figure 4. Key steps for data stitching, renaming and compression**  
**(a)** One example for correcting information of 'Stitching Image Grid Sequence', and a1 highlighted the replacement of red letters in step x about 'file names'. **(b)** The key information of 'TileConfiguration' txt file, b1 highlighted the responding channel number should be corrected and saved in respective separated folder and b2 highlighted the starting Z number should be '0000' for all 'TileConfiguration' files. **(c)** The information of 'Stitching.py'. **(d)** One example for settings of 'Multi-Rename Tool'. **(e)** One example of compressing tiff files with 'LZW TIFF'.








## Supplementary Figure 5. Key steps for Arivis fusion of 3D images


(a) One example of flipping one volumetric data of X or Y or Z direction to match with another volumetric data. (b) The overview of two volumetric data showing same XYZ directions after flipping. (c-d) Examples of identical structural markers from two volumetric data sets for fusion. (e) Loading of three key markers for best fusion. (f) 3D fused image of pancreas from two volumetric data sets.





### Supplementary Figure 6. Key steps for Imaris data loading and visualization

(a) One example of converting stitched image sequence data to the .ims format using Imaris File Converter. (b) The settings for file names with delimiter should be changed into “C \_ Z.tif”. (c) 3D image properties including XYZ voxel size and channel color can be set in Imaris for analysis.



### Supplementary Figure 7. Overview of SHANEL workflow

This workflow summarizes the main steps after organ collection: experimental setup (yellow), pretreatments (blue), labelling and clearing (grey) and imaging (red). We provided two ways of handling samples: active perfusion with pump, if the vessels could be connected with external tube, and passive incubation with shaker. Moreover, depending on the organ components, organ size, targeted labelling, and imaging structures, we outlined the differences in the whole process.